

# Jesus San Miguel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6789920/publications.pdf>

Version: 2024-02-01

1,067  
papers

92,194  
citations

334

137  
h-index

515

267  
g-index

1088  
all docs

1088  
docs citations

1088  
times ranked

36997  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014, 15, e538-e548.   | 5.1  | 3,343     |
| 2  | International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.  | 0.8  | 2,404     |
| 3  | Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2005, 352, 2487-2498.  | 13.9 | 2,356     |
| 4  | Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. <i>British Journal of Haematology</i> , 2003, 121, 749-757.           | 1.2  | 1,887     |
| 5  | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016, 17, e328-e346.  | 5.1  | 1,866     |
| 6  | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.   | 13.9 | 1,787     |
| 7  | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.   | 0.8  | 1,525     |
| 8  | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 357, 2123-2132.  | 13.9 | 1,365     |
| 9  | Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.   | 13.7 | 1,364     |
| 10 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.  | 13.9 | 1,210     |
| 11 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.   | 13.9 | 1,144     |
| 12 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.   | 13.9 | 1,139     |
| 13 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.   | 13.9 | 1,129     |
| 14 | Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. <i>Leukemia</i> , 1999, 13, 1901-1928.  | 3.3  | 1,038     |
| 15 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.   | 0.6  | 849       |
| 16 | Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 110-115. | 0.8  | 841       |
| 17 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> , 2008, 22, 414-423.   | 3.3  | 787       |
| 18 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.   | 13.9 | 747       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1055-1066.                                   | 5.1  | 710       |
| 20 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1195-1206. | 5.1  | 695       |
| 21 | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. <i>Leukemia</i> , 2009, 23, 215-224.   | 3.3  | 686       |
| 22 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.  | 0.6  | 686       |
| 23 | A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 1192-1200.  | 0.6  | 682       |
| 24 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.                          | 3.3  | 677       |
| 25 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.  | 3.3  | 664       |
| 26 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.   | 0.6  | 619       |
| 27 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.            | 0.8  | 607       |
| 28 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.   | 0.6  | 586       |
| 29 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.   | 0.6  | 512       |
| 30 | IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.  | 3.3  | 500       |
| 31 | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017, 31, 2094-2103.   | 3.3  | 486       |
| 32 | Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.  | 0.6  | 485       |
| 33 | Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. <i>New England Journal of Medicine</i> , 2013, 369, 438-447.  | 13.9 | 449       |
| 34 | New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. <i>Blood</i> , 2007, 110, 2586-2592.                                | 0.6  | 447       |
| 35 | Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.  | 0.6  | 438       |
| 36 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.   | 6.3  | 435       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.  | 0.6  | 429       |
| 38 | International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. <i>Leukemia</i> , 2009, 23, 1545-1556.  | 3.3  | 428       |
| 39 | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The. 2010, 11, 934-941.                 | 5.1  | 427       |
| 40 | Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.   | 0.6  | 425       |
| 41 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.  | 13.9 | 413       |
| 42 | Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.  | 0.8  | 403       |
| 43 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.   | 5.1  | 394       |
| 44 | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.  | 0.6  | 380       |
| 45 | Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.  | 0.6  | 377       |
| 46 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-398.  | 2.0  | 374       |
| 47 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. <i>Blood</i> , 2006, 108, 2165-2172.   | 0.6  | 373       |
| 48 | Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.   | 0.8  | 358       |
| 49 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.   | 0.6  | 335       |
| 50 | International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.   | 0.8  | 330       |
| 51 | Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. <i>Leukemia</i> , 1999, 13, 110-118. | 3.3  | 328       |
| 52 | Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001, 98, 1746-1751.   | 0.6  | 316       |
| 53 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.   | 0.6  | 316       |
| 54 | A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.   | 3.3  | 313       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.   | 0.6  | 309       |
| 56 | 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. <i>Leukemia Research</i> , 1983, 7, 51-55.  | 0.4  | 308       |
| 57 | Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 132-141.   | 6.3  | 299       |
| 58 | High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. <i>Blood</i> , 2005, 106, 3755-3759. | 0.6  | 298       |
| 59 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.  | 3.3  | 294       |
| 60 | International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.  | 0.8  | 294       |
| 61 | Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. <i>British Journal of Haematology</i> , 2003, 122, 394-403.  | 1.2  | 292       |
| 62 | Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.  | 13.9 | 291       |
| 63 | International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology, The</i> , 2019, 20, e302-e312.  | 5.1  | 290       |
| 64 | Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€”modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.   | 1.2  | 289       |
| 65 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.   | 0.6  | 285       |
| 66 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.  | 0.6  | 282       |
| 67 | Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.                      | 0.6  | 278       |
| 68 | High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.  | 0.6  | 274       |
| 69 | Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.                  | 0.8  | 263       |
| 70 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 781-794.   | 5.1  | 254       |
| 71 | Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014, 28, 384-390.   | 3.3  | 252       |
| 72 | Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , 2017, 31, 396-410.  | 7.7  | 251       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455. | 0.8 | 250       |
| 74 | Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.  | 0.8 | 248       |
| 75 | A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2008, 112, 3591-3593.                                  | 0.6 | 247       |
| 76 | The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. <i>Haematologica</i> , 2008, 93, 1301-1309.   | 1.7 | 243       |
| 77 | Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. <i>Blood</i> , 1997, 90, 2465-2470.  | 0.6 | 241       |
| 78 | Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. <i>Haematologica</i> , 2010, 95, 589-596.   | 1.7 | 240       |
| 79 | MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013, 27, 1722-1728.   | 3.3 | 238       |
| 80 | Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002, 100, 3121-3127.  | 0.6 | 236       |
| 81 | The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. <i>Cancer Research</i> , 2006, 66, 5781-5789.   | 0.4 | 233       |
| 82 | Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. <i>British Journal of Haematology</i> , 2001, 115, 575-582.  | 1.2 | 222       |
| 83 | Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-734.   | 0.8 | 221       |
| 84 | Minimal residual disease in leukaemia patients. <i>Lancet Oncology</i> , The, 2001, 2, 409-417.  | 5.1 | 217       |
| 85 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.   | 3.3 | 217       |
| 86 | Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. <i>Blood</i> , 2008, 112, 2709-2712.                                    | 0.6 | 213       |
| 87 | Therapy-Related Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2123-2137.   | 0.8 | 212       |
| 88 | Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.   | 3.2 | 212       |
| 89 | Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. <i>British Journal of Haematology</i> , 2001, 113, 1020-1034.   | 1.2 | 207       |
| 90 | International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). <i>Leukemia</i> , 2009, 23, 1904-1912.        | 3.3 | 207       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. <i>Leukemia</i> , 1999, 13, 419-427.   | 3.3 | 205       |
| 92  | Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016, 30, 1005-1017.  | 3.3 | 204       |
| 93  | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009, 114, 1729-1735.   | 0.6 | 203       |
| 94  | Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.  | 0.8 | 202       |
| 95  | The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009, 20, 1303-1317.   | 0.6 | 201       |
| 96  | Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. <i>Blood</i> , 2010, 115, 107-121.   | 0.6 | 201       |
| 97  | Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2737-2744.  | 0.8 | 193       |
| 98  | Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.   | 1.7 | 193       |
| 99  | Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10%549 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.   | 0.6 | 190       |
| 100 | Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , 2006, 107, 3575-3583.   | 0.6 | 188       |
| 101 | Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010, 24, 629-637.   | 3.3 | 188       |
| 102 | Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. <i>Leukemia</i> , 2007, 21, 541-549. | 3.3 | 187       |
| 103 | Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , 2010, 11, 1086-1095.  | 5.1 | 187       |
| 104 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi133-vi137.   | 0.6 | 187       |
| 105 | C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. <i>Blood</i> , 2014, 123, 4120-4131.   | 0.6 | 187       |
| 106 | Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096.   | 1.7 | 187       |
| 107 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , 2019, 393, 253-264.   | 6.3 | 187       |
| 108 | Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.  | 0.6 | 183       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.  | 15.2 | 179       |
| 110 | Isolation and Characterization of Mesenchymal Stromal Cells From Human Degenerated Nucleus Pulposus. <i>Spine</i> , 2010, 35, 2259-2265.  | 1.0  | 178       |
| 111 | IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.   | 0.6  | 178       |
| 112 | Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.   | 0.8  | 175       |
| 113 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.   | 2.2  | 174       |
| 114 | PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.   | 3.3  | 170       |
| 115 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.   | 2.8  | 170       |
| 116 | Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.  | 2.2  | 168       |
| 117 | Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002, 100, 2243-2245.   | 0.6  | 167       |
| 118 | Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007, 21, 143-150. | 3.3  | 167       |
| 119 | Immunophenotypic analysis of Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 187-195.  | 0.8  | 165       |
| 120 | Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. <i>Leukemia</i> , 2008, 22, 842-849.  | 3.3  | 163       |
| 121 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020, 34, 1875-1884.  | 3.3  | 163       |
| 122 | International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.   | 3.3  | 162       |
| 123 | The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2004, 18, 856-863.   | 3.3  | 157       |
| 124 | Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007, 110, 3112-3121.   | 0.6  | 157       |
| 125 | International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4521-4530.   | 0.8  | 156       |
| 126 | The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3176-3187.   | 3.2  | 156       |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.   | 0.8 | 154       |
| 128 | Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. <i>Blood</i> , 2013, 121, 884-892.  | 0.6 | 153       |
| 129 | Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.   | 0.8 | 150       |
| 130 | Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012, 120, 2581-2588.  | 0.6 | 148       |
| 131 | Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.   | 0.6 | 148       |
| 132 | Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1998, 16, 3774-3781.  | 0.8 | 147       |
| 133 | American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051. | 2.0 | 146       |
| 134 | Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.   | 0.6 | 146       |
| 135 | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.  | 1.7 | 144       |
| 136 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.  | 0.6 | 144       |
| 137 | Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. <i>Experimental Hematology</i> , 2008, 36, 1014-1021.  | 0.2 | 143       |
| 138 | Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.  | 0.8 | 142       |
| 139 | Chronic T cell lymphocytosis: a review of 21 cases. <i>British Journal of Haematology</i> , 1984, 58, 433-446.  | 1.2 | 140       |
| 140 | Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. <i>Blood</i> , 2002, 99, 1853-1856.   | 0.6 | 140       |
| 141 | Teclistamab, a B-cell maturation antigen-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.   | 6.3 | 138       |
| 142 | International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.   | 3.3 | 136       |
| 143 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.   | 5.1 | 136       |
| 144 | Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.   | 1.7 | 135       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. <i>Bone Marrow Transplantation</i> , 1997, 20, 451-458.  | 1.3 | 134       |
| 146 | Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.   | 1.7 | 132       |
| 147 | Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1404-1412.  | 0.8 | 131       |
| 148 | Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013, 122, 3591-3598.   | 0.6 | 131       |
| 149 | A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009, 114, 1166-1173.   | 0.6 | 129       |
| 150 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.   | 0.6 | 129       |
| 151 | BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. <i>Leukemia</i> , 2001, 15, 1185-1192.  | 3.3 | 128       |
| 152 | The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 1692-1700.  | 3.2 | 128       |
| 153 | Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2016, 17, 1127-1136.  | 5.1 | 128       |
| 154 | Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000, 111, 801-806.   | 1.2 | 127       |
| 155 | First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. <i>Blood</i> , 2019, 134, 143-143.  | 0.6 | 127       |
| 156 | Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. <i>Blood</i> , 2003, 101, 4695-4700.  | 0.6 | 126       |
| 157 | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , 2011, 86, 23-31.   | 1.1 | 126       |
| 158 | International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.  | 2.8 | 126       |
| 159 | Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.   | 0.6 | 125       |
| 160 | Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q <sup>23</sup> and 17p <sup>11</sup> ). <i>Clinical Cancer Research</i> , 2005, 11, 7757-7763. | 3.2 | 124       |
| 161 | Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. <i>Leukemia</i> , 2007, 21, 446-452.  | 3.3 | 124       |
| 162 | Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q <sup>31</sup> syndrome. <i>Leukemia</i> , 2009, 23, 664-672.   | 3.3 | 124       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.  | 0.8 | 123       |
| 164 | Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 120-126. | 0.8 | 122       |
| 165 | How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.   | 0.6 | 122       |
| 166 | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.   | 0.6 | 121       |
| 167 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.                                    | 2.2 | 121       |
| 168 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sup>E</sup>ELOQUENT follow-up and <sup>P</sup>post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.                           | 1.2 | 120       |
| 169 | Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015, 25, 478-487.   | 2.4 | 118       |
| 170 | New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , 2008, 9, 1157-1165.   | 5.1 | 116       |
| 171 | Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.  | 1.2 | 115       |
| 172 | Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.  | 0.8 | 115       |
| 173 | Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis. <i>Leukemia and Lymphoma</i> , 1998, 30, 459-466.  | 0.6 | 113       |
| 174 | Immunophenotypic Analysis of the TCR-V $\beta$ 2 Repertoire in 98 Persistent Expansions of CD3+/TCR- $\beta$ 2+ Large Granular Lymphocytes. <i>American Journal of Pathology</i> , 2001, 159, 1861-1868.   | 1.9 | 113       |
| 175 | The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , 2013, 27, 430-440.  | 3.3 | 112       |
| 176 | High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 1999, 107, 121-131.   | 1.2 | 110       |
| 177 | Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.   | 1.2 | 110       |
| 178 | Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 3661-3667.   | 3.2 | 109       |
| 179 | 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.   | 1.2 | 109       |
| 180 | Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 239-252.   | 0.7 | 109       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.   | 3.3 | 109       |
| 182 | Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. <i>British Journal of Haematology</i> , 1986, 64, 547-560.  | 1.2 | 108       |
| 183 | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011, 25, 749-760.  | 3.3 | 108       |
| 184 | Cell Surface Markers in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 1994, 69, 684-690.   | 1.4 | 107       |
| 185 | Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. <i>Leukemia</i> , 2002, 16, 1460-1469.   | 3.3 | 107       |
| 186 | Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. <i>Journal of Clinical Oncology</i> , 2007, 25, 4452-4458.      | 0.8 | 106       |
| 187 | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , 2012, 30, 1121-1131.  | 1.2 | 105       |
| 188 | BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia</i> , 2000, 14, 816-825.   | 3.3 | 104       |
| 189 | TCR $\beta$ <sup>+</sup> /CD4 <sup>+</sup> Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2003, 163, 763-771.   | 1.9 | 104       |
| 190 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2009, 82, 426-432.   | 1.1 | 104       |
| 191 | Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. <i>The Hematology Journal</i> , 2000, 1, 28-36.   | 2.0 | 104       |
| 192 | Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. <i>Leukemia</i> , 2002, 16, 1423-1431.   | 3.3 | 103       |
| 193 | Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 698-708. | 2.0 | 103       |
| 194 | Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. <i>Annals of Oncology</i> , 2000, 11, 441-444.  | 0.6 | 102       |
| 195 | Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. <i>British Journal of Haematology</i> , 2001, 115, 653-659.  | 1.2 | 102       |
| 196 | A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. <i>Oncologist</i> , 2006, 11, 51-61.   | 1.9 | 102       |
| 197 | Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. <i>British Journal of Haematology</i> , 2010, 148, 110-114.                      | 1.2 | 102       |
| 198 | Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.   | 0.6 | 102       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003, 102, 2994-3002.  | 0.6 | 101       |
| 200 | Busulfan 12 mg/kg plus melphalan 140 mg/m <sup>2</sup> versus melphalan 200 mg/m <sup>2</sup> as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920. | 1.7 | 101       |
| 201 | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.     | 0.6 | 101       |
| 202 | Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 438-446.   | 1.2 | 100       |
| 203 | Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 102, 1108-1113.  | 0.6 | 100       |
| 204 | SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. <i>Leukemia</i> , 2012, 26, 2521-2529.   | 3.3 | 100       |
| 205 | Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. <i>Hepatology</i> , 1997, 25, 1096-1100.   | 3.6 | 99        |
| 206 | Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 1135-1141.   | 1.3 | 98        |
| 207 | Aplidin, a Marine Organismâ€‘Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.   | 0.4 | 98        |
| 208 | Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.  | 0.6 | 98        |
| 209 | A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.  | 3.3 | 98        |
| 210 | Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.  | 1.2 | 95        |
| 211 | GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. <i>Blood</i> , 2014, 124, 1887-1893.  | 0.6 | 95        |
| 212 | Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. <i>British Journal of Haematology</i> , 1991, 77, 185-190.   | 1.2 | 94        |
| 213 | Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. <i>Leukemia</i> , 2001, 15, 406-414.   | 3.3 | 94        |
| 214 | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.  | 0.6 | 94        |
| 215 | Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. <i>Blood</i> , 2004, 103, 4056-4061.                                | 0.6 | 93        |
| 216 | Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. <i>Blood</i> , 2004, 104, 2661-2666.  | 0.6 | 92        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. <i>Haematologica</i> , 2009, 94, 1599-1602.  | 1.7 | 92        |
| 218 | The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017, 19, 218-224.  | 2.9 | 92        |
| 219 | Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e119-e130.   | 5.1 | 92        |
| 220 | Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.  | 1.2 | 91        |
| 221 | Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. <i>Haematologica</i> , 2003, 88, 555-60.  | 1.7 | 91        |
| 222 | Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>British Journal of Haematology</i> , 2003, 121, 104-108.  | 1.2 | 90        |
| 223 | European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.  | 1.9 | 90        |
| 224 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.  | 0.6 | 90        |
| 225 | Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.  | 2.8 | 90        |
| 226 | Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. <i>Haematologica</i> , 2004, 89, 58-69.  | 1.7 | 90        |
| 227 | Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. <i>American Journal of Pathology</i> , 2001, 158, 1843-1850.  | 1.9 | 88        |
| 228 | Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.  | 0.6 | 87        |
| 229 | TCR $\beta$ <sup>hi</sup> large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCR $\beta$ <sup>hi</sup> T-cells. <i>Leukemia</i> , 2006, 20, 505-513.  | 3.3 | 86        |
| 230 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-98.   | 2.0 | 86        |
| 231 | Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2167-2173.   | 0.8 | 85        |
| 232 | Comparative Analysis of the Morphological, Cytochemical, Immunophenotypical, and Functional Characteristics of Normal Human Peripheral Blood Lineage $\alpha^+$ /CD16 $\alpha^+$ /HLA-DR $\alpha^+$ /CD14 $\alpha^+$ /lo Cells, CD14 $\alpha^+$ Monocytes, and CD16 $\alpha^+$ Dendritic Cells. <i>Clinical Immunology</i> , 2001, 100, 325-338. | 1.4 | 85        |
| 233 | Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 402-409.  | 3.3 | 85        |
| 234 | Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1163-1171.         | 2.0 | 85        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. <i>Oncologist</i> , 2010, 15, 6-25.  | 1.9 | 85        |
| 236 | Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2001, 27, 511-515. | 1.3 | 84        |
| 237 | Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2001, 113, 161-171.   | 1.2 | 83        |
| 238 | Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. <i>Leukemia</i> , 2005, 19, 449-455.  | 3.3 | 83        |
| 239 | Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1448-1454.  | 2.0 | 83        |
| 240 | Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. <i>Haematologica</i> , 2012, 97, 1218-1224.  | 1.7 | 83        |
| 241 | Differentiation stage of myeloma plasma cells: biological and clinical significance. <i>Leukemia</i> , 2017, 31, 382-392.   | 3.3 | 83        |
| 242 | Multifunctional role of Erk5 in multiple myeloma. <i>Blood</i> , 2005, 105, 4492-4499.  | 0.6 | 82        |
| 243 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. <i>Haematologica</i> , 2008, 93, 560-565.  | 1.7 | 82        |
| 244 | Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. <i>Leukemia</i> , 2006, 20, 542-545.   | 3.3 | 81        |
| 245 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.   | 0.6 | 81        |
| 246 | Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.   | 2.8 | 81        |
| 247 | LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.   | 3.3 | 81        |
| 248 | The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 125, 2370-2380.   | 0.6 | 80        |
| 249 | Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021, 137, 49-60.   | 0.6 | 80        |
| 250 | Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. <i>British Journal of Haematology</i> , 1996, 95, 489-493.  | 1.2 | 79        |
| 251 | Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. <i>Leukemia</i> , 2008, 22, 1250-1255.  | 3.3 | 79        |
| 252 | Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.  | 3.3 | 79        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 1998, 38, 385-391.   | 0.8 | 78        |
| 254 | Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.   | 0.6 | 78        |
| 255 | Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009, 114, 148-152.  | 0.6 | 78        |
| 256 | Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1916-1923.  | 0.8 | 78        |
| 257 | A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. <i>Leukemia</i> , 2013, 27, 2056-2061.   | 3.3 | 78        |
| 258 | Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. <i>British Journal of Haematology</i> , 1990, 75, 26-33.   | 1.2 | 77        |
| 259 | Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. <i>Bone Marrow Transplantation</i> , 1998, 21, 133-140.   | 1.3 | 77        |
| 260 | Immunophenotyping of acute leukemias and myelodysplastic syndromes. , 2004, 58A, 62-71.  |     | 77        |
| 261 | Using quantification of the PML-RAR $\alpha$ transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 315-322.   | 1.7 | 77        |
| 262 | Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan $\alpha$ prednisone vs. melphalan $\alpha$ prednisone in the phase III VISTA trial in multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 372-384. | 1.1 | 77        |
| 263 | Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission. <i>Clinical Cancer Research</i> , 2013, 19, 4770-4779.  | 3.2 | 77        |
| 264 | Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. <i>British Journal of Haematology</i> , 2002, 118, 1034-1040.  | 1.2 | 76        |
| 265 | Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. <i>Leukemia</i> , 2003, 17, 2016-2024.  | 3.3 | 76        |
| 266 | Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 2761-2766.  | 0.8 | 76        |
| 267 | The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010, 24, 1700-1712.   | 3.3 | 76        |
| 268 | Multiparameter flow cytometry for the identification of the Waldenstr $\alpha$ m $\alpha$ clone in IgM-MGUS and Waldenstr $\alpha$ m $\alpha$ Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014, 28, 166-173.                     | 3.3 | 76        |
| 269 | Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. <i>Leukemia</i> , 2016, 30, 526-535.   | 3.3 | 76        |
| 270 | Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.   | 0.6 | 76        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Blood</i> , 2006, 107, 3415-3416. | 0.6 | 75        |
| 272 | Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. <i>Leukemia</i> , 2011, 25, 697-706.                 | 3.3 | 75        |
| 273 | Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013, 98, 640-648.  | 1.7 | 75        |
| 274 | Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. <i>Clinical Cancer Research</i> , 2014, 20, 1542-1554.   | 3.2 | 75        |
| 275 | Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 332-340.  | 2.3 | 75        |
| 276 | Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 1995, 90, 106-112.  | 1.2 | 74        |
| 277 | Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). <i>Blood Cancer Journal</i> , 2018, 8, 117.  | 2.8 | 74        |
| 278 | Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2003, 31, 387-392.   | 1.3 | 73        |
| 279 | Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012, 26, 1862-1869.   | 3.3 | 73        |
| 280 | Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples. <i>Analytical Cellular Pathology</i> , 1998, 16, 151-159.  | 2.1 | 72        |
| 281 | Conventional diagnostics in multiple myeloma. <i>European Journal of Cancer</i> , 2006, 42, 1510-1519.  | 1.3 | 72        |
| 282 | Can multiple myeloma become a curable disease?. <i>Haematologica</i> , 2011, 96, 1246-1248.   | 1.7 | 72        |
| 283 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.  | 3.3 | 72        |
| 284 | Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. <i>Journal of Hematology and Oncology</i> , 2016, 9, 113.  | 6.9 | 72        |
| 285 | Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. <i>Leukemia</i> , 2003, 17, 339-342.                     | 3.3 | 71        |
| 286 | Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2004, 127, 159-164.                           | 1.2 | 71        |
| 287 | Chronic Graft-Versus-Host Disease. <i>Drugs</i> , 2006, 66, 1041-1057.  | 4.9 | 71        |
| 288 | Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , 2015, 126, 921-922.  | 0.6 | 71        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015, 29, 1186-1194.  | 3.3 | 71        |
| 290 | Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their Behaviour. <i>Blood</i> , 2013, 122, 863-863.  | 0.6 | 71        |
| 291 | Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. <i>British Journal of Haematology</i> , 1985, 59, 277-296.   | 1.2 | 70        |
| 292 | Emerging therapies for the treatment of relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 1-15.   | 1.1 | 70        |
| 293 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930. | 0.8 | 70        |
| 294 | Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. <i>British Journal of Haematology</i> , 1996, 93, 81-88.   | 1.2 | 69        |
| 295 | Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000, 109, 138-147.                                     | 1.2 | 69        |
| 296 | Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. <i>Cancer Treatment Reviews</i> , 2005, 31, 591-602.  | 3.4 | 69        |
| 297 | Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. <i>Haematologica</i> , 2013, 98, 437-443.  | 1.7 | 69        |
| 298 | International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.  | 3.3 | 69        |
| 299 | A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. <i>Cytometry</i> , 1994, 17, 332-339.   | 1.8 | 68        |
| 300 | Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.  | 2.0 | 68        |
| 301 | Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.  | 1.7 | 68        |
| 302 | Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.  | 0.6 | 68        |
| 303 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.  | 3.3 | 68        |
| 304 | Mechanical, chemical and biological damage modes within headâ€¦neck tapers of CoCrMo and Ti6Al4V contemporary hip replacements. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 1672-1685.   | 1.6 | 68        |
| 305 | Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. <i>European Journal of Clinical Nutrition</i> , 1997, 51, 381-386.  | 1.3 | 67        |
| 306 | Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1279-1283.  | 1.3 | 67        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. <i>Journal of Clinical Investigation</i> , 2005, 115, 2351-2362.  | 3.9 | 67        |
| 308 | The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. <i>Blood</i> , 2009, 114, 4369-4372.               | 0.6 | 67        |
| 309 | Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. <i>Blood</i> , 2014, 124, 1300-1303.   | 0.6 | 67        |
| 310 | Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.   | 3.4 | 67        |
| 311 | Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. <i>Blood</i> , 2015, 126, 505-505.   | 0.6 | 67        |
| 312 | Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. <i>American Journal of Hematology</i> , 2005, 78, 302-305.   | 2.0 | 66        |
| 313 | Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.   | 3.4 | 66        |
| 314 | Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019, 134, 2218-2222.   | 0.6 | 66        |
| 315 | Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 341-347.  | 1.3 | 65        |
| 316 | The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. <i>Leukemia</i> , 2008, 22, 1479-1484.  | 3.3 | 65        |
| 317 | Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with <sc>VMP</sc> vs. <sc>MP</sc>: results from the <sc>VISTA</sc> trial. <i>European Journal of Haematology</i> , 2012, 89, 16-27. | 1.1 | 65        |
| 318 | Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. <i>Haematologica</i> , 2014, 99, 1365-1372.   | 1.7 | 65        |
| 319 | Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. <i>Haematologica</i> , 2002, 87, 609-14.                 | 1.7 | 65        |
| 320 | Management of multiple myeloma in the newly diagnosed patient. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 498-507.   | 0.9 | 64        |
| 321 | Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.  | 0.6 | 64        |
| 322 | High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. <i>Annals of Oncology</i> , 2003, 14, 140-151.                                     | 0.6 | 63        |
| 323 | Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. <i>Leukemia</i> , 2017, 31, 1922-1927.   | 3.3 | 63        |
| 324 | <sup>11</sup> C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. <i>Theranostics</i> , 2017, 7, 2956-2964.  | 4.6 | 63        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 325 | Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. <i>Cytometry</i> , 1997, 30, 98-102.   | 1.8  | 62        |
| 326 | Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.  | 3.2  | 62        |
| 327 | Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.  | 2.8  | 62        |
| 328 | Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2007, 12, E336-40.   | 0.7  | 62        |
| 329 | Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.. <i>Journal of Clinical Oncology</i> , 1993, 11, 1165-1171.   | 0.8  | 61        |
| 330 | Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.   | 1.1  | 61        |
| 331 | Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.. <i>Journal of Clinical Pathology</i> , 1996, 49, 15-18.  | 1.0  | 60        |
| 332 | Clinicobiological, Immunophenotypic, and Molecular Characteristics of Monoclonal CD56 <sup>+</sup> /+dim Chronic Natural Killer Cell Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2004, 165, 1117-1127.   | 1.9  | 60        |
| 333 | Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 29-37.              | 0.6  | 60        |
| 334 | Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74. | 2.0  | 60        |
| 335 | Treatment for High-Risk Smoldering Myeloma. <i>New England Journal of Medicine</i> , 2013, 369, 1762-1765.  | 13.9 | 60        |
| 336 | Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.   | 2.8  | 60        |
| 337 | Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , 2005, 114, 665-667.   | 2.3  | 59        |
| 338 | A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. <i>Haematologica</i> , 2009, 94, 364-371.   | 1.7  | 59        |
| 339 | Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. <i>Cytotherapy</i> , 2009, 11, 698-705.  | 0.3  | 59        |
| 340 | Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 38-43.                                  | 0.2  | 59        |
| 341 | The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. <i>Blood</i> , 2011, 117, 3613-3616.   | 0.6  | 59        |
| 342 | Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.                                    | 2.8  | 59        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Minimal residual disease monitoring by flow cytometry. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 599-612.   | 0.7 | 58        |
| 344 | Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a skewed TCR-V $\beta$ repertoire. <i>Cancer</i> , 2006, 106, 1296-1305. | 2.0 | 58        |
| 345 | The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , 2009, 23, 2265-2274.   | 3.3 | 58        |
| 346 | Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib+melfalan+prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.   | 2.0 | 58        |
| 347 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.   | 1.2 | 58        |
| 348 | Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-23 study. <i>British Journal of Haematology</i> , 2019, 186, e117-e121.  | 1.2 | 58        |
| 349 | Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2007, 92, 635-642.   | 1.7 | 57        |
| 350 | Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. <i>Blood Cancer Journal</i> , 2020, 10, 103.   | 2.8 | 57        |
| 351 | Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2021, 39, 1139-1149.   | 0.8 | 57        |
| 352 | De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. <i>Leukemia</i> , 2000, 14, 183-187.  | 3.3 | 56        |
| 353 | Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. <i>Leukemia</i> , 2003, 17, 1124-1129.   | 3.3 | 56        |
| 354 | The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , 2008, 93, 57-66.   | 1.7 | 56        |
| 355 | Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.  | 0.6 | 56        |
| 356 | Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. <i>Leukemia</i> , 2005, 19, 713-720.  | 3.3 | 55        |
| 357 | Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.   | 1.2 | 55        |
| 358 | Defining and treating high-risk multiple myeloma. <i>Leukemia</i> , 2015, 29, 2119-2125.  | 3.3 | 55        |
| 359 | Immunophenotype and DNA cell content in multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 735-759.   | 1.1 | 54        |
| 360 | Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. <i>British Journal of Haematology</i> , 2002, 118, 239-242.  | 1.2 | 54        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 361 | Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. <i>Leukemia</i> , 2004, 18, 491-498.   | 3.3  | 54        |
| 362 | Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 352-355.  | 1.4  | 54        |
| 363 | Redefining myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 494-496.   | 12.5 | 54        |
| 364 | Carfilzomib+“lenalidomide+“dexamethasone vs lenalidomide+“dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017, 7, e554-e554.   | 2.8  | 54        |
| 365 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427. | 5.1  | 54        |
| 366 | Iron metabolism and fungal infections in patients with haematological malignancies.. <i>Journal of Clinical Pathology</i> , 1995, 48, 223-225.  | 1.0  | 53        |
| 367 | Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: Comparative analysis of different stimuli, secretion-blocking agents and incubation periods. <i>Cytometry</i> , 2001, 46, 33-40.                                  | 1.8  | 53        |
| 368 | Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , 2003, 123, 858-868.  | 1.2  | 53        |
| 369 | Medium-term results of percutaneous vertebroplasty in multiple myeloma. <i>European Journal of Haematology</i> , 2006, 77, 7-13.  | 1.1  | 53        |
| 370 | Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.  | 0.6  | 53        |
| 371 | How should we treat newly diagnosed multiple myeloma patients?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 488-495.   | 0.9  | 53        |
| 372 | Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. <i>British Journal of Haematology</i> , 1986, 62, 75-83.   | 1.2  | 51        |
| 373 | Acute Lymphoblastic Leukemia (ALL): Detection of Minimal Residual Disease (MRD) at Flow Cytometry. <i>Leukemia and Lymphoma</i> , 1994, 13, 87-90.  | 0.6  | 51        |
| 374 | Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. <i>Haematologica</i> , 2009, 94, 975-983.   | 1.7  | 51        |
| 375 | Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.  | 0.6  | 51        |
| 376 | Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 27-27.   | 0.6  | 51        |
| 377 | Prognostic factors and classification in multiple myeloma. <i>British Journal of Cancer</i> , 1989, 59, 113-118.  | 2.9  | 50        |
| 378 | Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. , 1999, 60, 191-195.  |      | 50        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 379 | Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. <i>Leukemia</i> , 2001, 15, 840-845.  | 3.3 | 50        |
| 380 | Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. <i>Blood</i> , 2015, 126, 858-862.  | 0.6 | 50        |
| 381 | Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. <i>Haematologica</i> , 2018, 103, e318-e321.   | 1.7 | 50        |
| 382 | Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. <i>The Hematology Journal</i> , 2001, 2, 272-278.  | 2.0 | 50        |
| 383 | High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009, 33, 1706-1709.   | 0.4 | 49        |
| 384 | Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?. <i>Blood Reviews</i> , 2011, 25, 181-191.   | 2.8 | 49        |
| 385 | Blast Crisis of Chronic Granulocytic Leukemia with Mast Cell and Basophilic Precursors. <i>American Journal of Clinical Pathology</i> , 1985, 83, 254-259.  | 0.4 | 48        |
| 386 | Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. <i>Transplant Infectious Disease</i> , 2001, 3, 44-46.  | 0.7 | 48        |
| 387 | European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.   | 1.9 | 48        |
| 388 | Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.   | 2.8 | 48        |
| 389 | Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.  | 1.1 | 48        |
| 390 | Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk. <i>Gut</i> , 2016, 65, 1289-1295.  | 6.1 | 48        |
| 391 | A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560. | 1.2 | 48        |
| 392 | Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 241-245.  | 2.1 | 47        |
| 393 | Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. <i>American Journal of Hematology</i> , 2009, 84, 149-152.   | 2.0 | 47        |
| 394 | <i>p53</i> deletion may drive the clinical evolution and treatment response in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 359-361.  | 1.1 | 47        |
| 395 | Long FLT3 internal tandem duplications and reduced PML-RAR $\alpha$ expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010, 95, 745-751.   | 1.7 | 47        |
| 396 | Effects of MSC Coadministration and Route of Delivery on Cord Blood Hematopoietic Stem Cell Engraftment. <i>Cell Transplantation</i> , 2013, 22, 1171-1183.   | 1.2 | 47        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 397 | CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. <i>Haematologica</i> , 2011, 96, 328-332.   | 1.7 | 46        |
| 398 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154. | 5.1 | 46        |
| 399 | COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.   | 2.2 | 46        |
| 400 | The effect of vitamin D <sub>3</sub> metabolites on normal and leukemic bone marrow cells in vitro. <i>International Journal of Cell Cloning</i> , 1984, 2, 227-242.  | 1.6 | 45        |
| 401 | Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. <i>British Journal of Cancer</i> , 1993, 68, 1227-1231.  | 2.9 | 45        |
| 402 | Increased interleukin-12 serum levels in chronic alcoholism. <i>Journal of Hepatology</i> , 1998, 28, 771-777.  | 1.8 | 45        |
| 403 | Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.                                      | 0.6 | 45        |
| 404 | Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. <i>International Journal of Cancer</i> , 2004, 112, 884-889.  | 2.3 | 45        |
| 405 | Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. <i>Clinical Cancer Research</i> , 2013, 19, 2677-2687.   | 3.2 | 45        |
| 406 | Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.  | 1.2 | 45        |
| 407 | Increased expression of natural-killer-associated and activation antigens in multiple myeloma. <i>American Journal of Hematology</i> , 1992, 39, 84-89.   | 2.0 | 44        |
| 408 | Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. <i>PLoS ONE</i> , 2015, 10, e0121581.  | 1.1 | 44        |
| 409 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.   | 1.7 | 44        |
| 410 | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. <i>Leukemia</i> , 2017, 31, 1446-1449.  | 3.3 | 44        |
| 411 | Roadmap to cure multiple myeloma. <i>Cancer Treatment Reviews</i> , 2021, 100, 102284.  | 3.4 | 44        |
| 412 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , the, 2022, 9, e143-e161.  | 2.2 | 44        |
| 413 | High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. <i>Haematologica</i> , 2003, 88, 1372-7.                                 | 1.7 | 44        |
| 414 | Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. <i>Leukemia</i> , 2005, 19, 1088-1091.  | 3.3 | 43        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues. <i>Oncology</i> , 2006, 70, 474-482.   | 0.9 | 43        |
| 416 | Genomic analysis of high-risk smoldering multiple myeloma. <i>Haematologica</i> , 2012, 97, 1439-1443.  | 1.7 | 43        |
| 417 | Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.  | 0.6 | 43        |
| 418 | Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.                | 0.8 | 43        |
| 419 | Chronic graft-versus-host disease of the kidney in patients with allogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2013, 91, 129-134.   | 1.1 | 42        |
| 420 | NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4014-4025.   | 3.2 | 42        |
| 421 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122. | 1.7 | 42        |
| 422 | Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.  | 1.7 | 42        |
| 423 | The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008, 93, 1797-1805.  | 1.7 | 41        |
| 424 | The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e53-e55.  | 1.7 | 41        |
| 425 | Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?. <i>Clinical Cancer Research</i> , 2015, 21, 2001-2008.   | 3.2 | 41        |
| 426 | Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.   | 3.3 | 41        |
| 427 | Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.                                       | 0.6 | 41        |
| 428 | Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. <i>British Journal of Haematology</i> , 1995, 91, 941-943.  | 1.2 | 40        |
| 429 | Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. <i>British Journal of Haematology</i> , 1999, 104, 695-705.  | 1.2 | 40        |
| 430 | Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. <i>Bone Marrow Transplantation</i> , 2004, 34, 729-738.              | 1.3 | 40        |
| 431 | Prognostic Factors and Staging in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1115-1140.  | 0.9 | 40        |
| 432 | Bortezomib in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 701-715.  | 0.7 | 40        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 433 | BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010, 89, 453-458.   | 0.8 | 40        |
| 434 | How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.   | 0.2 | 40        |
| 435 | Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.                           | 0.2 | 40        |
| 436 | Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.  | 2.0 | 40        |
| 437 | Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.   | 0.8 | 40        |
| 438 | Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. <i>British Journal of Haematology</i> , 1995, 89, 338-341.   | 1.2 | 39        |
| 439 | Distribution of Peripheral Blood Lymphoid Subsets in Alcoholic Liver Cirrhosis: Influence of Ethanol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1564-1568.   | 1.4 | 39        |
| 440 | Alterations in Tumor Necrosis Factor-alpha, Interferon-gamma, and Interleukin-6 Production by Natural Killer Cell-Enriched Peripheral Blood Mononuclear Cells in Chronic Alcoholism: Relationship with Liver Disease and Ethanol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 1226-1231. | 1.4 | 39        |
| 441 | Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. , 1998, 34, 264-271.  |     | 39        |
| 442 | Lenalidomide: A new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008, 34, 283-291.  | 3.4 | 39        |
| 443 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 175, 448-456.   | 1.2 | 39        |
| 444 | Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 34.   | 2.8 | 39        |
| 445 | Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. <i>The Hematology Journal</i> , 2002, 3, 121-130.  | 2.0 | 39        |
| 446 | Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. <i>Haematologica</i> , 2006, 91, 621-7.  | 1.7 | 39        |
| 447 | Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain. <i>British Journal of Haematology</i> , 1999, 107, 667-669.  | 1.2 | 38        |
| 448 | Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. <i>Cancer</i> , 2003, 97, 601-609.   | 2.0 | 38        |
| 449 | Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. <i>Leukemia</i> , 2003, 17, 1398-1403.   | 3.3 | 38        |
| 450 | Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 317-325.   | 0.6 | 38        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 451 | Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.                  | 0.2 | 38        |
| 452 | Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment. <i>PLoS ONE</i> , 2011, 6, e26241.   | 1.1 | 38        |
| 453 | Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. <i>Clinical Cancer Research</i> , 2012, 18, 2145-2163.   | 3.2 | 38        |
| 454 | A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. <i>British Journal of Haematology</i> , 2015, 170, 804-813.                              | 1.2 | 38        |
| 455 | Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. <i>Leukemia</i> , 2018, 32, 971-978.  | 3.3 | 38        |
| 456 | Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.    | 0.6 | 38        |
| 457 | Immunophenotypical detection of minimal residual disease in acute leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 175-185.  | 2.0 | 37        |
| 458 | The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. <i>Transfusion</i> , 2002, 42, 1159-1172.  | 0.8 | 37        |
| 459 | FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. <i>The Hematology Journal</i> , 2004, 5, 239-246.  | 2.0 | 37        |
| 460 | A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.  | 3.3 | 37        |
| 461 | The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. <i>British Journal of Haematology</i> , 1999, 106, 400-405.  | 1.2 | 36        |
| 462 | Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 936-941.   | 2.0 | 36        |
| 463 | Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. <i>British Journal of Haematology</i> , 2013, 162, 474-482. | 1.2 | 36        |
| 464 | Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. <i>Haematologica</i> , 2013, 98, 279-287.   | 1.7 | 36        |
| 465 | Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. <i>World Journal of Stem Cells</i> , 2014, 6, 322.  | 1.3 | 36        |
| 466 | Immunophenotypic analysis of myelodysplastic syndromes. <i>Haematologica</i> , 2003, 88, 402-7.  | 1.7 | 36        |
| 467 | Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. <i>Annals of Hematology</i> , 1993, 67, 217-222.  | 0.8 | 35        |
| 468 | Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. <i>The Hematology Journal</i> , 2004, 5, 227-233.   | 2.0 | 35        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 469 | The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 141, 470-482.                              | 1.2 | 35        |
| 470 | Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. <i>Blood Reviews</i> , 2009, 23, 87-93.  | 2.8 | 35        |
| 471 | Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 775-790.  | 0.9 | 35        |
| 472 | Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. <i>American Journal of Pathology</i> , 2016, 186, 2171-2182.   | 1.9 | 35        |
| 473 | Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020, 30, 1217-1227.  | 2.4 | 35        |
| 474 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.                     | 3.3 | 35        |
| 475 | Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. , 1998, 34, 223-228.   |     | 34        |
| 476 | IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. <i>British Journal of Haematology</i> , 1998, 103, 163-167.                      | 1.2 | 34        |
| 477 | CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.                                   | 1.7 | 34        |
| 478 | Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.  | 4.9 | 34        |
| 479 | Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. <i>Blood</i> , 2016, 127, 3035-3039.  | 0.6 | 34        |
| 480 | Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1991, 79, 408-414.   | 1.2 | 33        |
| 481 | Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. <i>Blood</i> , 2003, 102, 2699-2700.                                  | 0.6 | 33        |
| 482 | CD34+ Cells from Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistanceâ€™ Associated Phenotypes. <i>Clinical Cancer Research</i> , 2004, 10, 7599-7606. | 3.2 | 33        |
| 483 | Prognostic features of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 569-583.   | 0.7 | 33        |
| 484 | Deficient Spindle Assembly Checkpoint in Multiple Myeloma. <i>PLoS ONE</i> , 2011, 6, e27583.   | 1.1 | 33        |
| 485 | Living at Higher Altitude and Incidence of Overweight/Obesity: Prospective Analysis of the SUN Cohort. <i>PLoS ONE</i> , 2016, 11, e0164483.  | 1.1 | 33        |
| 486 | Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.   | 1.2 | 33        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 487 | Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 23-28.   | 0.5 | 32        |
| 488 | Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. <i>British Journal of Haematology</i> , 2006, 133, 642-645.  | 1.2 | 32        |
| 489 | The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib. <i>Oncologist</i> , 2007, 12, 281-290.   | 1.9 | 32        |
| 490 | Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.  | 2.0 | 32        |
| 491 | DNA Cell Content Studies in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1996, 23, 33-41.   | 0.6 | 31        |
| 492 | Treatment of Multiple Myeloma in Elderly People: Long-term Results in 178 Patients. <i>Age and Ageing</i> , 1996, 25, 357-361.  | 0.7 | 31        |
| 493 | Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 901-905.  | 1.3 | 31        |
| 494 | Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial. <i>British Journal of Haematology</i> , 2003, 120, 296-303. | 1.2 | 31        |
| 495 | Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. <i>Haematologica</i> , 2008, 93, 851-859.  | 1.7 | 31        |
| 496 | Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 117-124.  | 1.1 | 31        |
| 497 | Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2012, 181, 1879-1888.   | 1.9 | 31        |
| 498 | Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.  | 3.3 | 31        |
| 499 | Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. <i>Haematologica</i> , 2005, 90, 54-9.   | 1.7 | 31        |
| 500 | Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 1309-1318.   | 2.5 | 31        |
| 501 | A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma. <i>Blut</i> , 1990, 60, 319-322.   | 1.2 | 30        |
| 502 | p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. <i>The Hematology Journal</i> , 2001, 2, 146-149.  | 2.0 | 30        |
| 503 | Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 212-215.   | 1.2 | 29        |
| 504 | Limbus Damage in Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 270-273.  | 2.0 | 29        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 505 | Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011, 96, 468-471.     | 1.7 | 29        |
| 506 | Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.  | 0.4 | 29        |
| 507 | Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.  | 0.6 | 29        |
| 508 | B-cell chronic lymphocytic leukaemia: Prognostic value of the immunophenotype and the clinico-haematological features. <i>American Journal of Hematology</i> , 1989, 31, 26-31.  | 2.0 | 28        |
| 509 | Prognostic value of Sâ€phase cells in AML patients. <i>British Journal of Haematology</i> , 1995, 89, 342-348.   | 1.2 | 28        |
| 510 | Abnormalities of Peripheral Blood T Lymphocytes and Natural Killer Cells in Alcoholic Hepatitis Persist after a 3-Month Withdrawal Period. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 672-676.                                  | 1.4 | 28        |
| 511 | Neurological Complications after Autologous Stem Cell Transplantation. <i>European Neurology</i> , 1999, 41, 48-50.  | 0.6 | 28        |
| 512 | Immunophenotyping of Plasma Cells in Multiple Myeloma. , 2005, 113, 5-24.  |     | 28        |
| 513 | The role of immature platelet fraction in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 103, 247-249.   | 1.8 | 28        |
| 514 | Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 768-773.  | 0.6 | 28        |
| 515 | Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016, 22, 4206-4214.   | 3.2 | 28        |
| 516 | Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. <i>Leukemia</i> , 2021, 35, 1438-1450.   | 3.3 | 28        |
| 517 | Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1866-1866.     | 0.6 | 28        |
| 518 | Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246. | 0.6 | 28        |
| 519 | Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. <i>Haematologica</i> , 2002, 87, 822-7.               | 1.7 | 28        |
| 520 | Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkinâ€™s lymphomas. <i>Leukemia</i> , 1997, 11, 1915-1920.  | 3.3 | 27        |
| 521 | Sequential analysis of CD34+ and CD34â€™ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. <i>Leukemia</i> , 2001, 15, 430-439.                              | 3.3 | 27        |
| 522 | Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 105-118.  | 0.7 | 27        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 523 | Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. <i>Leukemia</i> , 2003, 17, 1051-1057.   | 3.3 | 27        |
| 524 | Clinical applicability and prognostic significance of molecular response assessed by fluorescently labeled PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. <i>British Journal of Haematology</i> , 2013, 163, 581-589.   | 1.2 | 27        |
| 525 | Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.  | 1.7 | 27        |
| 526 | Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. <i>Annals of Hematology</i> , 2016, 95, 2033-2041.                                      | 0.8 | 27        |
| 527 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.   | 0.6 | 27        |
| 528 | Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e26-e27.   | 0.2 | 27        |
| 529 | An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 176-176.   | 0.6 | 27        |
| 530 | A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 509-509.  | 0.6 | 27        |
| 531 | Distribution of the CD45R antigen in the maturation of lymphoid and myeloid series: the CD45R negative phenotype is a constant finding in T CD4 positive lymphoproliferative disorders. <i>British Journal of Haematology</i> , 1988, 69, 173-179.  | 1.2 | 26        |
| 532 | Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society) <i>TJ ETQq0 03rgBT /Ozlock 10</i>  | 0.6 | 26        |
| 533 | Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. <i>British Journal of Haematology</i> , 2002, 119, 135-143.  | 1.2 | 26        |
| 534 | Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447. | 2.0 | 26        |
| 535 | Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. <i>Cytotherapy</i> , 2007, 9, 14-22.  | 0.3 | 26        |
| 536 | Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , 2007, 21, 797-804.  | 3.3 | 26        |
| 537 | Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. <i>Oncologist</i> , 2011, 16, 388-403.   | 1.9 | 26        |
| 538 | Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.   | 3.3 | 26        |
| 539 | Laparoscopic Diagnosis of Tuberculous Ascites. <i>Endoscopy</i> , 1982, 14, 178-179.  | 1.0 | 25        |
| 540 | Flow cytometry in the diagnosis of cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 145-152.  | 0.6 | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 541 | Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 664-671.                               | 2.0 | 25        |
| 542 | Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. <i>International Journal of Cancer</i> , 2009, 124, 367-375. | 2.3 | 25        |
| 543 | The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.  | 1.1 | 25        |
| 544 | Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.  | 6.9 | 25        |
| 545 | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.  | 3.1 | 25        |
| 546 | Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.   | 1.7 | 25        |
| 547 | T-cell subpopulations in patients with monoclonal gammopathies: Essential monoclonal gammopathy, multiple myeloma, and Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 1985, 20, 267-273.  | 2.0 | 24        |
| 548 | Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. <i>British Journal of Haematology</i> , 1995, 89, 104-109.   | 1.2 | 24        |
| 549 | Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. <i>Cytometry</i> , 1995, 22, 217-222.  | 1.8 | 24        |
| 550 | Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. <i>Bone Marrow Transplantation</i> , 2000, 25, 217-218.   | 1.3 | 24        |
| 551 | Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. <i>British Journal of Haematology</i> , 2002, 117, 890-892.   | 1.2 | 24        |
| 552 | CD34 <sup>+</sup> cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.  | 0.6 | 24        |
| 553 | Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. <i>Haematologica</i> , 2007, 92, 1295-1296.  | 1.7 | 24        |
| 554 | Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 618-633.  | 0.8 | 24        |
| 555 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.  | 2.0 | 24        |
| 556 | Introduction to a series of reviews on multiple myeloma. <i>Blood</i> , 2015, 125, 3039-3040.   | 0.6 | 24        |
| 557 | Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.   | 1.3 | 24        |
| 558 | Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.   | 1.0 | 24        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.  | 2.1 | 24        |
| 560 | Measurable residual disease in multiple myeloma: ready for clinical practice?. <i>Journal of Hematology and Oncology</i> , 2020, 13, 82.   | 6.9 | 24        |
| 561 | 18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. <i>Cancers</i> , 2020, 12, 1042.  | 1.7 | 24        |
| 562 | Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.   | 0.6 | 24        |
| 563 | Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.   | 2.6 | 24        |
| 564 | Detection of the Mbcrl/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implications for minimal residual disease detection. <i>Human Pathology</i> , 1997, 28, 154-159.   | 1.1 | 23        |
| 565 | Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 1229-1230.   | 1.3 | 23        |
| 566 | Renin Expression in Hematological Malignancies and its Role in the Regulation of Hematopoiesis. <i>Leukemia and Lymphoma</i> , 2002, 43, 2377-2381.  | 0.6 | 23        |
| 567 | HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 1448-1454.  | 0.6 | 23        |
| 568 | Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e92378.  | 1.1 | 23        |
| 569 | Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 155-162.   | 1.7 | 23        |
| 570 | Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.   | 0.6 | 23        |
| 571 | Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414. | 2.2 | 23        |
| 572 | Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992, 82, 671-675.   | 1.2 | 22        |
| 573 | Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005 <65y Trials. <i>American Journal of Pathology</i> , 2012, 181, 1870-1878. | 1.9 | 22        |
| 574 | Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.                                   | 1.7 | 22        |
| 575 | Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 353-366.   | 0.9 | 22        |
| 576 | A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 99-106.  | 1.2 | 22        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 577 | Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. <i>Hematological Oncology</i> , 2017, 35, 746-751.   | 0.8 | 22        |
| 578 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 785-798. | 0.2 | 22        |
| 579 | 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.   | 1.7 | 22        |
| 580 | Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan vs Prednisone Versus Melphalan vs Prednisone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 650-650.   | 0.6 | 22        |
| 581 | Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.                   | 0.6 | 22        |
| 582 | Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux. <i>Blood</i> , 2016, 128, 1151-1151.                  | 0.6 | 22        |
| 583 | Development of acute leukaemia after idiopathic myelofibrosis. <i>Journal of Clinical Pathology</i> , 1992, 45, 427-430.   | 1.0 | 21        |
| 584 | Clonality analysis for antigen receptor genes: Preliminary results from the biomed-2 concerted action PL 96-3936. <i>Human Pathology</i> , 2003, 34, 359-361.  | 1.1 | 21        |
| 585 | Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 183-187.  | 1.3 | 21        |
| 586 | Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. <i>Oncologist</i> , 2008, 13, 82-92.   | 1.9 | 21        |
| 587 | Effect of vitamin D treatment in chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1395-1397.   | 1.3 | 21        |
| 588 | Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 207-217.   | 3.2 | 21        |
| 589 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.   | 1.1 | 21        |
| 590 | CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. <i>Journal of Clinical Medicine</i> , 2020, 9, 3577.   | 1.0 | 21        |
| 591 | Preneoplastic somatic mutations including MYD88 <sup>L265P</sup> in lymphoplasmacytic lymphoma. <i>Science Advances</i> , 2022, 8, eabl4644.   | 4.7 | 21        |
| 592 | The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. <i>Haematologica</i> , 2004, 89, 1213-8.   | 1.7 | 21        |
| 593 | Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. <i>Leukemia</i> , 2001, 15, 121-127.   | 3.3 | 20        |
| 594 | Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 1086-1091.  | 0.8 | 20        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 595 | Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015, 100, 1207-1213.   | 1.7 | 20        |
| 596 | Utility of flow cytometry studies in the management of patients with multiple myeloma. <i>Current Opinion in Oncology</i> , 2016, 28, 511-517.   | 1.1 | 20        |
| 597 | Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.  | 3.3 | 20        |
| 598 | First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.  | 3.2 | 20        |
| 599 | One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156. | 0.6 | 20        |
| 600 | Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). <i>Blood</i> , 2016, 128, 1149-1149.   | 0.6 | 20        |
| 601 | Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. <i>Haematologica</i> , 2005, 90, 906-13.  | 1.7 | 20        |
| 602 | A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1996, 94, 140-147.  | 1.2 | 19        |
| 603 | Two new 3?PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.   |     | 19        |
| 604 | Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012, 97, 616-621.  | 1.7 | 19        |
| 605 | Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1075-1087.   | 1.9 | 19        |
| 606 | Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. <i>Haematologica</i> , 2015, 100, 1096-102.  | 1.7 | 19        |
| 607 | Multiple Myeloma Minimal Residual Disease. <i>Cancer Treatment and Research</i> , 2016, 169, 103-122.  | 0.2 | 19        |
| 608 | Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.  | 1.7 | 19        |
| 609 | FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.  | 2.5 | 19        |
| 610 | A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. <i>Blood</i> , 2010, 116, 307-307.                                       | 0.6 | 19        |
| 611 | Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. <i>Blood</i> , 2017, 130, 838-838.   | 0.6 | 19        |
| 612 | Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.                             | 0.6 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 613 | CYTOKINE THERAPY IN MULTIPLE MYELOMA*. British Journal of Haematology, 1996, 94, 425-432.   | 1.2 | 18        |
| 614 | Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. British Journal of Haematology, 2000, 109, 658-660.  | 1.2 | 18        |
| 615 | The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia, 2000, 14, 1493-1499.                       | 3.3 | 18        |
| 616 | Functional class switch recombination may occur "in vivo" in Waldenström macroglobulinaemia. British Journal of Haematology, 2007, 136, 114-116.  | 1.2 | 18        |
| 617 | Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 2008, 93, 1343-1350.  | 1.7 | 18        |
| 618 | The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Annals of Hematology, 2013, 92, 97-100.  | 0.8 | 18        |
| 619 | Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. British Journal of Haematology, 2016, 173, 754-768.   | 1.2 | 18        |
| 620 | Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS ONE, 2018, 13, e0203392.  | 1.1 | 18        |
| 621 | A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526. | 1.7 | 18        |
| 622 | Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.  | 1.7 | 18        |
| 623 | Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.   | 2.5 | 18        |
| 624 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. Blood, 2019, 134, 859-859.            | 0.6 | 18        |
| 625 | Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. Blood, 2017, 130, 905-905.   | 0.6 | 18        |
| 626 | Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone. Haematologica, 2006, 91, 331-9.   | 1.7 | 18        |
| 627 | Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.   | 2.5 | 18        |
| 628 | The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. Blut, 1986, 52, 357-363.  | 1.2 | 17        |
| 629 | Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplantation, 1999, 23, 997-1002.              | 1.3 | 17        |
| 630 | Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 289-293.   | 1.3 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 631 | Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. <i>Transfusion</i> , 2001, 41, 1212-1216.  | 0.8 | 17        |
| 632 | Bone remodeling markers are useful in the management of monoclonal gammopathies. <i>The Hematology Journal</i> , 2004, 5, 480-488.   | 2.0 | 17        |
| 633 | Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. <i>Leukemia Research</i> , 2006, 30, 943-948.   | 0.4 | 17        |
| 634 | Both CD133 <sup>+</sup> Cells and Monocytes Provide Significant Improvement for Hindlimb Ischemia, Although They do not Transdifferentiate Into Endothelial Cells. <i>Cell Transplantation</i> , 2010, 19, 103-112.  | 1.2 | 17        |
| 635 | Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 168-171.   | 0.2 | 17        |
| 636 | Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. <i>Haematologica</i> , 2012, 97, 1608-1611.  | 1.7 | 17        |
| 637 | New Approaches to Smoldering Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 270-276.  | 1.2 | 17        |
| 638 | Multiple myeloma: a model for scientific and clinical progress. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 1-7.  | 0.9 | 17        |
| 639 | The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. <i>Leukemia</i> , 2015, 29, 1435-1437.  | 3.3 | 17        |
| 640 | Origin of Waldenström's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 136-147.   | 0.7 | 17        |
| 641 | Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment. <i>Haematologica</i> , 2020, 105, e470-473.   | 1.7 | 17        |
| 642 | Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3245-3245.   | 0.6 | 17        |
| 643 | Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. <i>Blood</i> , 2018, 132, 3272-3272. | 0.6 | 17        |
| 644 | A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2008, 112, 2781-2781.  | 0.6 | 17        |
| 645 | Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. <i>Bone Marrow Transplantation</i> , 2002, 30, 63-68.  | 1.3 | 16        |
| 646 | Should prophylactic granulocyte colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?. <i>British Journal of Haematology</i> , 2008, 140, 324-326.   | 1.2 | 16        |
| 647 | How to treat a newly diagnosed young patient with multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 555-565.  | 0.9 | 16        |
| 648 | Performance evaluation of triple-branch GSC diversity receivers over generalized-K fading channels. <i>IEEE Communications Letters</i> , 2009, 13, 829-831.  | 2.5 | 16        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 649 | First report of the nipa palm hispid <i>Octodonta nipae</i> on queen palms in Cyprus. <i>Phytoparasitica</i> , 2011, 39, 51-54.  | 0.6 | 16        |
| 650 | Uptake and delivery of antigens by mesenchymal stromal cells. <i>Cytotherapy</i> , 2013, 15, 673-678.  | 0.3 | 16        |
| 651 | The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , 2016, 33, 1896-1920.   | 1.3 | 16        |
| 652 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.  | 1.2 | 16        |
| 653 | Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.  | 2.8 | 16        |
| 654 | Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016, 128, 3307-3307.    | 0.6 | 16        |
| 655 | Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. <i>Blood</i> , 2017, 130, 743-743. | 0.6 | 16        |
| 656 | Ligand-dependent transformation by the receptor for human granulocyte/macrophage colony-stimulating factor and tyrosine phosphorylation of the receptor beta subunit.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3963-3967.       | 3.3 | 15        |
| 657 | Myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 1996, 23, 57-93.   | 2.0 | 15        |
| 658 | Heterogeneity of structural abnormalities in the 7q31.3-q34 region in myeloid malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 136-143.  | 1.0 | 15        |
| 659 | Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2006, 37, 337-338.  | 1.3 | 15        |
| 660 | The DAC system and associations with multiple myeloma. <i>Investigational New Drugs</i> , 2010, 28, 28-35.   | 1.2 | 15        |
| 661 | Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 1187-1195.  | 1.7 | 15        |
| 662 | The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. <i>Haematologica</i> , 2012, 97, 1329-1337.  | 1.7 | 15        |
| 663 | Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative <scp>PCR</scp> in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 89, 328-335.  | 1.1 | 15        |
| 664 | Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. <i>Annals of Oncology</i> , 2015, 26, 2247-2256.   | 0.6 | 15        |
| 665 | Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. <i>Hematological Oncology</i> , 2018, 36, 463-470.   | 0.8 | 15        |
| 666 | Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.  | 2.5 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 667 | Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.  | 0.6 | 15        |
| 668 | Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 2105-2105.  | 0.6 | 15        |
| 669 | Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.                               | 0.8 | 15        |
| 670 | Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). <i>European Journal of Cancer</i> , 1993, 29, 57-60.  | 1.3 | 14        |
| 671 | Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 665-672. | 1.3 | 14        |
| 672 | Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines. <i>Journal of Clinical Oncology</i> , 2009, 27, 5676-5677.   | 0.8 | 14        |
| 673 | Frequency of HLAâ€A, â€B and â€DRB1 specificities and haplotypic associations in the population of Castilla y LeÃ3n (northwestâ€central Spain). <i>Tissue Antigens</i> , 2011, 78, 249-255.  | 1.0 | 14        |
| 674 | Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment. <i>Leukemia Research</i> , 2012, 36, 895-899.  | 0.4 | 14        |
| 675 | Human Bone Marrow Stromal Cells Differentiate into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice. <i>Cell Transplantation</i> , 2015, 24, 2423-2433.   | 1.2 | 14        |
| 676 | Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.   | 2.8 | 14        |
| 677 | Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.  | 0.6 | 14        |
| 678 | Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3187-3187.  | 0.6 | 14        |
| 679 | A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.  | 3.2 | 14        |
| 680 | Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 202.  | 2.8 | 14        |
| 681 | TdT activity in acute myeloid leukemias defined by monoclonal antibodies. <i>American Journal of Hematology</i> , 1986, 23, 9-17.  | 2.0 | 13        |
| 682 | Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. <i>Clinical Immunology and Immunopathology</i> , 1988, 46, 177-185.  | 2.1 | 13        |
| 683 | The Relationship Between Hyperthyroidism and the Distribution of Peripheral Blood T, NK and B-Lymphocytes in Multinodular Goiter. <i>Hormone and Metabolic Research</i> , 1994, 26, 104-108.   | 0.7 | 13        |
| 684 | Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype.. <i>Journal of Clinical Pathology</i> , 1995, 48, 456-462.   | 1.0 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 685 | Debate Round-Table: Comments concerning chimerism studies. <i>Leukemia</i> , 2001, 15, 1986-1988.  | 3.3 | 13        |
| 686 | Analysis of Methylation Pattern in Multiple Myeloma. <i>Acta Haematologica</i> , 2005, 114, 23-26.   | 0.7 | 13        |
| 687 | Long-term Immune Recovery of Patients Undergoing Allogeneic Stem Cell Transplantation: A Comparison with Their Respective Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 354-361.  | 2.0 | 13        |
| 688 | Relevance of renin expression by real-time PCR in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 409-416.  | 0.6 | 13        |
| 689 | Molecular biology of myeloma. <i>Clinical and Translational Oncology</i> , 2007, 9, 618-624.   | 1.2 | 13        |
| 690 | Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1331-1336.  | 2.0 | 13        |
| 691 | Characterization of haematological parameters with bortezomib+melphalan+prednisone versus melphalan+prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221. | 1.2 | 13        |
| 692 | Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.   | 1.7 | 13        |
| 693 | Multiple myeloma: treatment evolution. <i>Hematology</i> , 2012, 17, s3-s6.  | 0.7 | 13        |
| 694 | Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. <i>Leukemia</i> , 2014, 28, 1747-1750.   | 3.3 | 13        |
| 695 | Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.  | 1.7 | 13        |
| 696 | Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1703-1712.  | 2.0 | 13        |
| 697 | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.   | 2.8 | 13        |
| 698 | Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , 2021, 194, 132-139.  | 1.2 | 13        |
| 699 | VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.   | 0.6 | 13        |
| 700 | An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1850-1850.   | 0.6 | 13        |
| 701 | Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).. <i>Blood</i> , 2007, 110, 2712-2712.   | 0.6 | 13        |
| 702 | Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan+Prednisone Versus Melphalan+Prednisone. <i>Blood</i> , 2008, 112, 2778-2778.   | 0.6 | 13        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 703 | New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 2096-2096.   | 0.6 | 13        |
| 704 | Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 161-161.   | 0.6 | 13        |
| 705 | Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. <i>Blood</i> , 2021, 138, 1647-1647.  | 0.6 | 13        |
| 706 | Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .  | 2.0 | 13        |
| 707 | Immunophenotypic characterisation of acute leukaemia after polycythemia vera.. <i>Journal of Clinical Pathology</i> , 1993, 46, 668-671.   | 1.0 | 12        |
| 708 | Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. <i>Annals of Hematology</i> , 1997, 75, 81-86.   | 0.8 | 12        |
| 709 | Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2002, 119, 883-884.   | 1.2 | 12        |
| 710 | Consolidation therapy in myeloma: a consolidated approach?. <i>Blood</i> , 2012, 120, 2-3.   | 0.6 | 12        |
| 711 | Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. <i>Annals of Hematology</i> , 2012, 91, 1887-1895. | 0.8 | 12        |
| 712 | Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. <i>Leukemia Research Reports</i> , 2015, 4, 64-69.  | 0.2 | 12        |
| 713 | A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018, 103, 880-889.  | 1.7 | 12        |
| 714 | Exposureâ€Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 614-627.                                    | 1.0 | 12        |
| 715 | Covidâ€19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021, 96, 896-900.  | 2.0 | 12        |
| 716 | Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex). <i>Blood</i> , 2020, 136, 8-9.                                       | 0.6 | 12        |
| 717 | Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. <i>Blood</i> , 2015, 126, 721-721.  | 0.6 | 12        |
| 718 | Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDt-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2021, 138, 1829-1829.          | 0.6 | 12        |
| 719 | MRD in multiple myeloma: does CR really matter?. <i>Blood</i> , 2022, 140, 2423-2428.  | 0.6 | 12        |
| 720 | Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. <i>Transfusion Medicine</i> , 2012, 22, 122-127.  | 0.5 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 721 | RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , 2013, 31, 200-205.  | 1.2 | 11        |
| 722 | Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. <i>Cancer Cell</i> , 2015, 28, 281-283.   | 7.7 | 11        |
| 723 | Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.  | 0.6 | 11        |
| 724 | Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. <i>Blood Cancer Journal</i> , 2019, 9, 36.   | 2.8 | 11        |
| 725 | Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.  | 1.1 | 11        |
| 726 | Daratumumab With Cetrelimab, an Anti-“PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 46-54.e4.  | 0.2 | 11        |
| 727 | Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. <i>Leukemia</i> , 2021, 35, 3012-3016.  | 3.3 | 11        |
| 728 | Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.  | 0.6 | 11        |
| 729 | Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.   | 1.7 | 11        |
| 730 | Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8002-8002. | 0.8 | 11        |
| 731 | Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. <i>Oncotarget</i> , 2016, 7, 80664-80679.   | 0.8 | 11        |
| 732 | Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. <i>Haematologica</i> , 2003, 88, 1013-21.  | 1.7 | 11        |
| 733 | Alpha interferon in the management of essential thrombocythaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, S72-S74.   | 0.9 | 10        |
| 734 | Rhabdomyolysis associated with septicemia after autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 95-95.  | 1.3 | 10        |
| 735 | Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 1997, 74, 79-82.  | 0.8 | 10        |
| 736 | Pathologic rupture of the spleen during induction with ATRA in a patient with acute promyelocytic leukemia. <i>Medical Oncology</i> , 2000, 17, 337-339.   | 1.2 | 10        |
| 737 | Immunologic monitoring in adults with acute lymphoblastic leukemia. <i>Current Oncology Reports</i> , 2003, 5, 413-418.  | 1.8 | 10        |
| 738 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. <i>Bone Marrow Transplantation</i> , 2004, 34, 675-682.                               | 1.3 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 739 | Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability. <i>Experimental Hematology</i> , 2005, 33, 935-943.   | 0.2 | 10        |
| 740 | Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. <i>Hematological Oncology</i> , 2006, 24, 205-211.   | 0.8 | 10        |
| 741 | Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e289-e291.   | 1.7 | 10        |
| 742 | Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.  | 3.3 | 10        |
| 743 | Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1996-1996.                                      | 0.6 | 10        |
| 744 | Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 408-408. | 0.6 | 10        |
| 745 | Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma. <i>Blood</i> , 2015, 126, 117-117.   | 0.6 | 10        |
| 746 | High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 482-482.   | 0.6 | 10        |
| 747 | A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 1192-1200.  | 0.6 | 10        |
| 748 | New Tools for Diagnosis and Monitoring of Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e313-e318.  | 1.8 | 10        |
| 749 | Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.   | 1.1 | 10        |
| 750 | Cytogenetic Heterogeneity in Clonal Plasma Cell Disorders: A Study in Highly Purified Aberrant Plasma Cells. <i>Blood</i> , 2012, 120, 3945-3945.  | 0.6 | 10        |
| 751 | Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2022, 39, 1976-1992.   | 1.3 | 10        |
| 752 | A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. <i>Hybridoma</i> , 1985, 4, 369-378.   | 0.9 | 9         |
| 753 | An abnormal CD34+myeloid/CD34+lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. , 1999, 38, 70-75.   |     | 9         |
| 754 | Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 68-72.   | 1.0 | 9         |
| 755 | Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 573-579.  | 1.4 | 9         |
| 756 | The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2010, 84, 266-270.   | 1.1 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 757 | Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. <i>Haematologica</i> , 2017, 102, 168-175.   | 1.7 | 9         |
| 758 | The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. <i>Leukemia and Lymphoma</i> , 2020, 61, 680-690.   | 0.6 | 9         |
| 759 | Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora's Box of Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1430.   | 1.7 | 9         |
| 760 | Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences. <i>American Journal of Hematology</i> , 1993, 43, 256-258.  | 2.0 | 8         |
| 761 | Sequential intravenous-oral ciprofloxacin plus amoxicillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. <i>Hematology and Cell Therapy</i> , 1997, 39, 223-227.   | 0.7 | 8         |
| 762 | Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. <i>Leukemia Research</i> , 2004, 28, 1181-1187.  | 0.4 | 8         |
| 763 | New Tools for Diagnosis and Monitoring of Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e313-e318.  | 1.8 | 8         |
| 764 | Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?. <i>Haematologica</i> , 2014, 99, 5-6.  | 1.7 | 8         |
| 765 | Initial treatment of transplant-ineligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 67-77.  | 1.0 | 8         |
| 766 | Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 625-628.  | 1.2 | 8         |
| 767 | Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.   | 3.3 | 8         |
| 768 | Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530. | 1.2 | 8         |
| 769 | Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. <i>BMC Cancer</i> , 2021, 21, 659.   | 1.1 | 8         |
| 770 | Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>The Hematology Journal</i> , 2003, 4, 67-70.  | 2.0 | 8         |
| 771 | Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 2006-2006.   | 0.6 | 8         |
| 772 | Incidence, Clinical Features, and Outcome of All-Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1998, 92, 2712-2718.  | 0.6 | 8         |
| 773 | Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study. <i>Blood</i> , 2021, 138, 1677-1677.  | 0.6 | 8         |
| 774 | A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.   | 2.8 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 775 | T cells subpopulations in untreated and treated patients with haemophilia A and B. <i>Blut</i> , 1983, 47, 311-313.  | 1.2 | 7         |
| 776 | Myelodysplastic syndrome evolving to a mixed myeloid-lymphoid leukaemia. <i>Hematological Oncology</i> , 1986, 4, 175-176.   | 0.8 | 7         |
| 777 | Heterogeneity of T cell lymphoblastic leukaemias.. <i>Journal of Clinical Pathology</i> , 1991, 44, 628-631.   | 1.0 | 7         |
| 778 | Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34 <sup>+</sup> bone marrow cell compartments from patients with myelodysplastic syndromes. <i>Leukemia</i> , 2004, 18, 1311-1313.  | 3.3 | 7         |
| 779 | Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 1725-1729.  | 0.6 | 7         |
| 780 | Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. <i>Thrombosis Research</i> , 2007, 119, 691-698.   | 0.8 | 7         |
| 781 | Prospective comparative analysis of the angiogenic capacity of monocytes and CD133+ cells in a murine model of hind limb ischemia. <i>Cytotherapy</i> , 2009, 11, 1041-1051.   | 0.3 | 7         |
| 782 | Risk Stratification in the Era of Novel Therapies. <i>Cancer Journal (Sudbury, Mass )</i> , 2009, 15, 457-464.   | 1.0 | 7         |
| 783 | Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 113-119.   | 1.2 | 7         |
| 784 | MyelomaA Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 796-800.  | 0.6 | 7         |
| 785 | Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 223-234.   | 1.2 | 7         |
| 786 | Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 19-28.  | 2.3 | 7         |
| 787 | Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 504-516.   | 1.9 | 7         |
| 788 | Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e16-e17.   | 0.2 | 7         |
| 789 | Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.   | 1.7 | 7         |
| 790 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 480-489. | 0.2 | 7         |
| 791 | Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , 2021, 5, 1340-1343.   | 2.5 | 7         |
| 792 | Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2018, 132, 2142-2142.  | 0.6 | 7         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 793 | Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology, 2013, 31, 8527-8527. | 0.8  | 7         |
| 794 | Long-Term Reversibility of Renal Dysfunction Associated to Light Chain Deposition Disease with Bortezomib and Dexamethasone and High Dose Therapy and Autologous Stem Cell Transplantation. Clinics and Practice, 2011, 1, 205-208.                                      | 0.6  | 7         |
| 795 | Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma. Blood, 2010, 116, 617-617.   | 0.6  | 7         |
| 796 | Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. Blood, 2021, 138, 76-76.   | 0.6  | 7         |
| 797 | Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. Blood, 2021, 138, 544-544.   | 0.6  | 7         |
| 798 | CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. Blood, 2021, 138, 735-735.   | 0.6  | 7         |
| 799 | OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S17-S18.      | 0.2  | 7         |
| 800 | HELPER/SUPPRESSOR T-CELL SUBPOPULATIONS IN BENIGN PARAPROTEINAEMIA. British Journal of Haematology, 1983, 54, 318-320.   | 1.2  | 6         |
| 801 | Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias. International Journal of Laboratory Hematology, 1985, 7, 359-368.  | 0.2  | 6         |
| 802 | In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis. Leukemia Research, 1997, 21, 651-656.  | 0.4  | 6         |
| 803 | Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. Bone Marrow Transplantation, 2004, 33, 579-587.   | 1.3  | 6         |
| 804 | Prognostic Impact of Pretransplantation Computed Tomography and Gallium Scans in Patients with Hodgkin Lymphoma with Poor Prognosis Undergoing Hematopoietic Stem Cell Transplantation. Clinical Lymphoma and Myeloma, 2006, 7, 217-225.                                 | 1.4  | 6         |
| 805 | Smoldering Multiple Myeloma: When to Observe and When to Treat?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e484-e492.   | 1.8  | 6         |
| 806 | V. Smoldering multiple myeloma. Hematological Oncology, 2015, 33, 33-37.   | 0.8  | 6         |
| 807 | Improved understanding of disease biology and treatment. Nature Reviews Clinical Oncology, 2015, 12, 71-72.  | 12.5 | 6         |
| 808 | Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 2020, 55, 419-430.  | 1.3  | 6         |
| 809 | Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study. British Journal of Haematology, 2021, 194, e48-e51.   | 1.2  | 6         |
| 810 | Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 413-420.  | 0.2  | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 811 | Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. <i>Blood</i> , 2019, 134, 506-506.  | 0.6 | 6         |
| 812 | Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2020, 136, 10-11.  | 0.6 | 6         |
| 813 | The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. <i>Blood</i> , 2007, 110, 410-410. | 0.6 | 6         |
| 814 | A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. <i>Blood</i> , 2011, 118, 3962-3962.   | 0.6 | 6         |
| 815 | Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study. <i>Blood</i> , 2013, 122, 1968-1968.                  | 0.6 | 6         |
| 816 | Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 178-178.   | 0.6 | 6         |
| 817 | Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. <i>Blood</i> , 2014, 124, 3465-3465.   | 0.6 | 6         |
| 818 | The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 5190-5190.                    | 0.6 | 6         |
| 819 | Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. <i>Blood</i> , 2021, 138, 1739-1739.               | 0.6 | 6         |
| 820 | Bone marrow necrosis and treatment with interferon.. <i>Journal of Clinical Pathology</i> , 1986, 39, 1045-1045.  | 1.0 | 5         |
| 821 | DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers. <i>Cytometry</i> , 1995, 22, 22-25.   | 1.8 | 5         |
| 822 | In vitro autonomous proliferation in ANLL: Clinical and biological significance. <i>Leukemia Research</i> , 1995, 19, 411-416.  | 0.4 | 5         |
| 823 | Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.. <i>Journal of Clinical Pathology</i> , 1996, 49, 450-452.  | 1.0 | 5         |
| 824 | Clonal myelodysplastic cells present in apheresis product before transplantation. <i>Leukemia</i> , 1998, 12, 1497-1499.  | 3.3 | 5         |
| 825 | Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia. <i>Leukemia</i> , 1999, 13, 485-487.   | 3.3 | 5         |
| 826 | Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. <i>Clinical Biochemistry</i> , 2000, 33, 415-418.  | 0.8 | 5         |
| 827 | Myeloma: Update on supportive care strategies. <i>Current Treatment Options in Oncology</i> , 2003, 4, 247-258.   | 1.3 | 5         |
| 828 | Cell Cycle Analysis of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 250-252.  | 2.1 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 829 | Bone marrow mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation. <i>Experimental Hematology</i> , 2006, 34, 7.  | 0.2 | 5         |
| 830 | Frontline Treatment in Elderly Patients With Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 133-142.   | 1.8 | 5         |
| 831 | Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e17-e18.  | 0.2 | 5         |
| 832 | Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 567-569.   | 1.3 | 5         |
| 833 | Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e1-e2.  | 0.2 | 5         |
| 834 | Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e15-e16.  | 0.2 | 5         |
| 835 | Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018, 132, 3278-3278.               | 0.6 | 5         |
| 836 | Bortezomib+Melphalan+Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. <i>Blood</i> , 2008, 112, 1727-1727.  | 0.6 | 5         |
| 837 | Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 3026-3026. | 0.6 | 5         |
| 838 | Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8526-8526.             | 0.8 | 5         |
| 839 | Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.   | 2.8 | 5         |
| 840 | Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.   | 0.8 | 5         |
| 841 | Method for the simultaneous labelling of terminal deoxynucleotidyl transferase (TdT) and membrane antigens.. <i>Journal of Clinical Pathology</i> , 1984, 37, 628-632.  | 1.0 | 4         |
| 842 | CYTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF MONOCLONAL GAMMOPATHIES. <i>British Journal of Haematology</i> , 1985, 60, 768-769.  | 1.2 | 4         |
| 843 | PLASMA BLASTIC MULTIPLE MYELOMA: AN IMMUNOLOGICALLY DIFFERENT SUBTYPE. <i>British Journal of Haematology</i> , 1987, 66, 275-281.   | 1.2 | 4         |
| 844 | HYBRID ACUTE LEUKAEMIA. <i>British Journal of Haematology</i> , 1987, 67, 117-118.  | 1.2 | 4         |
| 845 | Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia. <i>Blut</i> , 1988, 57, 19-23.  | 1.2 | 4         |
| 846 | Translocation(15;17)(q22;q21) in a patient with Klinefelter syndrome. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 86.   | 1.0 | 4         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 847 | Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders. <i>Annals of Hematology</i> , 1997, 74, 209-214.  | 0.8 | 4         |
| 848 | TCR-gamma gene rearrangement with interstitial deletion within the TRGV2 gene segment is not detected in normal T-lymphocytes. <i>Leukemia</i> , 1998, 12, 251-253.  | 3.3 | 4         |
| 849 | Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. , 1999, 38, 24-29.  |     | 4         |
| 850 | Effect of High Altitude on Protein Metabolism in Bolivian Children. <i>High Altitude Medicine and Biology</i> , 2002, 3, 377-386.  | 0.5 | 4         |
| 851 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2004, 5, 285-285.  | 2.0 | 4         |
| 852 | In leukapheresis products from non-Hodgkinâ€™s lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression. <i>Transfusion and Apheresis Science</i> , 2007, 37, 145-156.   | 0.5 | 4         |
| 853 | Clinical and Prognostic Value of Discrepancies in Microsatellite DNA Regions Between Recipient and Donor in Human Leukocyte Antigen-Identical Allogeneic Transplantation Setting. <i>Transplantation</i> , 2008, 86, 983-990.  | 0.5 | 4         |
| 854 | Influence of antiplatelet-anticoagulant drugs on the need of blood components transfusion after vesical transurethral resection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2015, 87, 136.  | 0.4 | 4         |
| 855 | Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update. <i>Blood</i> , 2019, 134, 3152-3152.   | 0.6 | 4         |
| 856 | Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019, 134, 694-694.                   | 0.6 | 4         |
| 857 | Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. <i>Blood</i> , 2008, 112, 1741-1741.   | 0.6 | 4         |
| 858 | Sustained Response After Short-Medium-Term Treatment With Eltrombopag In Patients With ITP. <i>Blood</i> , 2013, 122, 2323-2323.   | 0.6 | 4         |
| 859 | Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2013, 122, 403-403.  | 0.6 | 4         |
| 860 | Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 2120-2120. | 0.6 | 4         |
| 861 | Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 3390-3390.  | 0.6 | 4         |
| 862 | Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.   | 0.6 | 4         |
| 863 | Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN). <i>Blood</i> , 2015, 126, 4180-4180.   | 0.6 | 4         |
| 864 | Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. <i>Blood</i> , 2013, 122, 3723-3723.   | 0.6 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 865 | Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902. | 0.6 | 4         |
| 866 | Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma. <i>Haematologica</i> , 2005, 90, 78-85.                         | 1.7 | 4         |
| 867 | Hypertriglyceridemia in Patients with Typhoid Fever. <i>Journal of Infectious Diseases</i> , 1983, 147, 606-606.   | 1.9 | 3         |
| 868 | Changes in surface antigens of HL-60 cells during differentiation in vitro. <i>Blut</i> , 1984, 49, 369-373.   | 1.2 | 3         |
| 869 | Letter to the editor: T-cell subsets and myeloma cell mass. <i>American Journal of Hematology</i> , 1987, 25, 235-236.   | 2.0 | 3         |
| 870 | Skin involvement in non-secretory myeloma. <i>American Journal of Medicine</i> , 1988, 84, 373-374.  | 0.6 | 3         |
| 871 | Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, S48-S49.   | 0.9 | 3         |
| 872 | The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. <i>Annals of Hematology</i> , 1994, 68, 233-236.  | 0.8 | 3         |
| 873 | Multiparametric cell-cycle analysis of peripheral blood-activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd. <i>Cytometry</i> , 1996, 25, 317-323.   | 1.8 | 3         |
| 874 | Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection. <i>British Journal of Haematology</i> , 1996, 93, 251-252.   | 1.2 | 3         |
| 875 | A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses. <i>Annals of Hematology</i> , 2003, 82, 750-758.                                   | 0.8 | 3         |
| 876 | Evolving Treatment Strategies for Anaemia in Cancer: Experience with Epoetin Beta. <i>Oncology</i> , 2004, 67, 17-22.  | 0.9 | 3         |
| 877 | The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. <i>Tissue Antigens</i> , 2008, 71, 548-551.  | 1.0 | 3         |
| 878 | Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma. <i>Medicina Clínica</i> , 2017, 148, 517-523.   | 0.3 | 3         |
| 879 | Waldenström's Macroglobulinemia Immunophenotype. , 2017, , 21-34.  |     | 3         |
| 880 | Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e164-e165.                     | 0.2 | 3         |
| 881 | Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. <i>British Journal of Haematology</i> , 2020, 189, 860-868.  | 1.2 | 3         |
| 882 | Two new PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 35-43.   | 1.5 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 883 | Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. <i>Blood</i> , 2018, 132, 112-112.  | 0.6 | 3         |
| 884 | Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 1943-1943.   | 0.6 | 3         |
| 885 | Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1510-1510.   | 0.6 | 3         |
| 886 | Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 2155-2155.  | 0.6 | 3         |
| 887 | Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. <i>Blood</i> , 2014, 124, 4742-4742.  | 0.6 | 3         |
| 888 | Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients. <i>Blood</i> , 2015, 126, 2971-2971.  | 0.6 | 3         |
| 889 | Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015, 126, 3031-3031.  | 0.6 | 3         |
| 890 | OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S3-S4.                                      | 0.2 | 3         |
| 891 | The research mission in myeloma. <i>Leukemia</i> , 2009, 23, 422-423.   | 3.3 | 2         |
| 892 | Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. <i>Leukemia Research</i> , 2009, 33, 170-173.   | 0.4 | 2         |
| 893 | Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. <i>American Journal of Hematology</i> , 2010, 85, 290-293.   | 2.0 | 2         |
| 894 | Prognosis and Staging of Multiple Myeloma. , 2013, , 615-636.   |     | 2         |
| 895 | Lección Magistral Andrés Laguna: el tratamiento del mieloma múltiple. <i>Revista Clínica Española</i> , 2014, 214, 466-469.   | 0.2 | 2         |
| 896 | Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e75-e76. | 0.2 | 2         |
| 897 | KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). <i>Annals of Oncology</i> , 2016, 27, viii16.  | 0.6 | 2         |
| 898 | CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S330.  | 0.2 | 2         |
| 899 | Diagnosis and Staging of Multiple Myeloma and Related Disorders. <i>Hematologic Malignancies</i> , 2018, , 17-28.   | 0.2 | 2         |
| 900 | Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e47.  | 0.2 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 901 | Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison. <i>Blood</i> , 2018, 132, 3553-3553.   | 0.6 | 2         |
| 902 | Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 433-433.  | 0.6 | 2         |
| 903 | Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis. <i>Blood</i> , 2018, 132, 4741-4741.   | 0.6 | 2         |
| 904 | The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD). <i>Blood</i> , 2019, 134, 509-509.   | 0.6 | 2         |
| 905 | Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. <i>Blood</i> , 2013, 122, 2939-2939.                            | 0.6 | 2         |
| 906 | MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). <i>Blood</i> , 2013, 122, 3198-3198.                      | 0.6 | 2         |
| 907 | Dual Antitumoral and Bone Antiresorptive Effect Of The Pan-Pim Kinase Inhibitor, LGH447, In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4435-4435.   | 0.6 | 2         |
| 908 | Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.                             | 0.6 | 2         |
| 909 | Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2014, 124, 3457-3457.  | 0.6 | 2         |
| 910 | Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. <i>Blood</i> , 2014, 124, 3532-3532.   | 0.6 | 2         |
| 911 | Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.   | 0.6 | 2         |
| 912 | Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 367-367.   | 0.6 | 2         |
| 913 | Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). <i>Blood</i> , 2015, 126, 4243-4243. | 0.6 | 2         |
| 914 | Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.  | 0.6 | 2         |
| 915 | Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. <i>Blood</i> , 2016, 128, 3308-3308.   | 0.6 | 2         |
| 916 | Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4442-4442.  | 0.6 | 2         |
| 917 | Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. <i>Blood</i> , 2016, 128, 4503-4503.   | 0.6 | 2         |
| 918 | Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs). <i>Blood</i> , 2016, 128, 801-801.  | 0.6 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 919 | Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8511-8511.  | 0.8 | 2         |
| 920 | Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenström's Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.. Blood, 2005, 106, 503-503.                        | 0.6 | 2         |
| 921 | ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).. Blood, 2007, 110, 2721-2721.   | 0.6 | 2         |
| 922 | Bortezomib in the Upfront Treatment of Multiple Myeloma. , 2011, , 53-68.   |     | 2         |
| 923 | Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. Blood, 2014, 124, 25-25.   | 0.6 | 2         |
| 924 | Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. Blood, 2014, 124, 2001-2001.  | 0.6 | 2         |
| 925 | The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. Blood, 2015, 126, 4181-4181.  | 0.6 | 2         |
| 926 | P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S134-S135. | 0.2 | 2         |
| 927 | Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. Blood, 2021, 138, 1662-1662.                              | 0.6 | 2         |
| 928 | Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies. Blood, 2021, 138, 541-541.   | 0.6 | 2         |
| 929 | Osteolytic lesion as the presenting feature of chronic granulocytic leukaemia. International Journal of Laboratory Hematology, 1985, 7, 105-112.  | 0.2 | 1         |
| 930 | Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. Clinical Immunology and Immunopathology, 1985, 35, 139-145.  | 2.1 | 1         |
| 931 | Peculiar cytogenetic finding in T-cell lymphoproliferative disorders. Cancer Genetics and Cytogenetics, 1985, 17, 185-186.  | 1.0 | 1         |
| 932 | Chronic polymphocytoid leukaemia with an unusual immature immunophenotype.. Journal of Clinical Pathology, 1994, 47, 461-463.   | 1.0 | 1         |
| 933 | Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma. Journal of Molecular Diagnostics, 2006, 8, 364-370.  | 1.2 | 1         |
| 934 | Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. Annals of Nuclear Medicine, 2008, 22, 251-260.               | 1.2 | 1         |
| 935 | Reply to "Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114. Haematologica, 2013, 98, e10-e10.                   | 1.7 | 1         |
| 936 | Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. Clinical Case Reports (discontinued), 2016, 4, 1096-1100.   | 0.2 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 937 | How deep is the myeloma iceberg?. Blood, 2018, 132, 2424-2425.  | 0.6 | 1         |
| 938 | Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S253.                                | 0.2 | 1         |
| 939 | Role of lncRNAs as prognostic factor and potential therapeutic target in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e354-e355.  | 0.2 | 1         |
| 940 | FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e94.   | 0.2 | 1         |
| 941 | PS1395 COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE. HemaSphere, 2019, 3, 640.   | 1.2 | 1         |
| 942 | Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM). Blood, 2018, 132, 4436-4436.  | 0.6 | 1         |
| 943 | VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. Blood, 2018, 132, 4446-4446.   | 0.6 | 1         |
| 944 | A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE). Blood, 2019, 134, 2144-2144.                                   | 0.6 | 1         |
| 945 | MicroRNA Expression Profiling in Multiple Myeloma: Correlation with Genetic Abnormalities. Blood, 2008, 112, 629-629.   | 0.6 | 1         |
| 946 | Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,. Blood, 2011, 118, 3936-3936.  | 0.6 | 1         |
| 947 | Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression. Blood, 2013, 122, 1973-1973. | 0.6 | 1         |
| 948 | Tumor and Renal Response in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. Blood, 2014, 124, 4776-4776.                                  | 0.6 | 1         |
| 949 | Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. Blood, 2015, 126, 2962-2962.  | 0.6 | 1         |
| 950 | The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone. Blood, 2015, 126, 5354-5354.   | 0.6 | 1         |
| 951 | What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood, 2015, 126, 725-725.  | 0.6 | 1         |
| 952 | Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. Blood, 2016, 128, 3436-3436.   | 0.6 | 1         |
| 953 | Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 373-373.  | 0.6 | 1         |
| 954 | Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma. Blood, 2016, 128, 4420-4420.   | 0.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 955 | The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. <i>Blood</i> , 2016, 128, 5688-5688.   | 0.6 | 1         |
| 956 | Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8583-8583.   | 0.8 | 1         |
| 957 | Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2740-2740.  | 0.6 | 1         |
| 958 | Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. <i>Blood</i> , 2007, 110, 729-729. | 0.6 | 1         |
| 959 | The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 5192-5192.   | 0.6 | 1         |
| 960 | A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).. <i>Blood</i> , 2009, 114, 4140-4140.  | 0.6 | 1         |
| 961 | Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010, 116, 1963-1963.   | 0.6 | 1         |
| 962 | Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies. <i>Blood</i> , 2010, 116, 1916-1916.   | 0.6 | 1         |
| 963 | Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. <i>Blood</i> , 2011, 118, 3951-3951.   | 0.6 | 1         |
| 964 | Myelodysplasia-Associated Immunophenotypic Abnormalities of Bone Marrow (BM) Cells in Multiple Myeloma (MM): Are They Present At Diagnosis or Can Be Induced by Lenalidomide?. <i>Blood</i> , 2011, 118, 5066-5066.   | 0.6 | 1         |
| 965 | Phase II Optimization, Open-Label Clinical Trial of Zalzypis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 4041-4041.  | 0.6 | 1         |
| 966 | Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3188-3188.   | 0.6 | 1         |
| 967 | Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3448-3448.   | 0.6 | 1         |
| 968 | The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016, 128, 375-375.   | 0.6 | 1         |
| 969 | Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 1995-1995.  | 0.6 | 1         |
| 970 | Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 3064-3064.   | 0.6 | 1         |
| 971 | Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. <i>Blood</i> , 2019, 134, 1773-1773.  | 0.6 | 1         |
| 972 | Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimism Trial By Patient Age and Prior Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3120-3120.   | 0.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 973 | The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549. | 0.6 | 1         |
| 974 | Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3762-3762.  | 0.6 | 1         |
| 975 | Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 1852-1852.  | 0.6 | 1         |
| 976 | LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.   | 0.6 | 1         |
| 977 | Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.   | 0.6 | 1         |
| 978 | Landscape and clinical significance of long noncoding <i>lncRNAs</i> involved in multiple myeloma expressed fusion transcripts. <i>American Journal of Hematology</i> , 2022, 97, .   | 2.0 | 1         |
| 979 | Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-14.   | 0.6 | 1         |
| 980 | Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma. , 2022, , 173-176.   |     | 1         |
| 981 | Prognostic value of serum paraprotein response kinetics in patients with newly diagnosed multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .   | 0.2 | 1         |
| 982 | Aortoduodenal fistula: Gastrointestinal bleeding and polymicrobial sepsis. <i>Digestive Diseases and Sciences</i> , 1982, 27, 1142-1143.  | 1.1 | 0         |
| 983 | Biphenotypic leukemia in treated Hodgkin's disease.. <i>Journal of Clinical Pathology</i> , 1984, 37, 1314-1315.  | 1.0 | 0         |
| 984 | LEPTOSPIRAS VERSUS LIBERTY. <i>Lancet</i> , The, 1986, 328, 295.  | 6.3 | 0         |
| 985 | Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1417-1418.   | 0.9 | 0         |
| 986 | Validation of survival-predictive models in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 1989, 30, 44-44.   | 2.0 | 0         |
| 987 | Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients. <i>American Journal of Hematology</i> , 1994, 46, 158-159.   | 2.0 | 0         |
| 988 | Reply to Nowak et al. <i>British Journal of Haematology</i> , 2000, 110, 752-753.   | 1.2 | 0         |
| 989 | Reply to Yanamandra et al. <i>British Journal of Haematology</i> , 2003, 120, 1096-1096.  | 1.2 | 0         |
| 990 | Myeloma. <i>Oncology Times</i> , 2006, 28, 20-21.   | 0.1 | 0         |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 991  | The Activity of Spanish and Italian Myeloma Groups. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S36-S39.   | 1.4 | 0         |
| 992  | Introduction and overview. <i>Blood Reviews</i> , 2010, 24, S1-S3.   | 2.8 | 0         |
| 993  | Concluding remarks and future directions. <i>Blood Reviews</i> , 2010, 24, S33-S34.  | 2.8 | 0         |
| 994  | Reply to A. Gratwohl. <i>Journal of Clinical Oncology</i> , 2011, 29, e484-e484.   | 0.8 | 0         |
| 995  | Application of D-Case to the Data-Upload Flow Diagram Scenario of the Distributed E-Learning System Called KISSEL. , 2012, , .   |     | 0         |
| 996  | Asymptomatic (smoldering) myeloma: treatment strategy. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 445-453.  | 0.7 | 0         |
| 997  | Can CRd be a standard for refractory myeloma?. <i>Blood</i> , 2013, 122, 3092-3093.  | 0.6 | 0         |
| 998  | Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma. <i>Value in Health</i> , 2014, 17, A546.                                   | 0.1 | 0         |
| 999  | San-Miguel J, Blad   J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti  IL-6) in multiple myeloma. <i>Blood</i> . 2014;123(26):4136-4142.. <i>Blood</i> , 2014, 124, 1201-1201.              | 0.6 | 0         |
| 1000 | Authors  ™ Response. <i>American Journal of Hematology</i> , 2015, 90, 146-146.  | 2.0 | 0         |
| 1001 | Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. <i>Medicina Cl  nica (English Edition)</i> , 2017, 148, 517-523.   | 0.1 | 0         |
| 1002 | Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e4-e5. | 0.2 | 0         |
| 1003 | Autologous hematopoietic cell transplants for plasma cell myeloma: One, two, or none?. , 0, , 445-457.   |     | 0         |
| 1004 | Risk Stratification in Newly Diagnosed Smoldering Multiple Myeloma. , 2018, , 1-13.  |     | 0         |
| 1005 | Smoldering Multiple Myeloma. , 2018, , 531-538.  |     | 0         |
| 1006 | Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e32-e33.   | 0.2 | 0         |
| 1007 | MM-339: Effect of Lenalidomide (R)    Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S306-S307.      | 0.2 | 0         |
| 1008 | Monocyte counts: an early index of haemopoietic reconstitution after peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2000, 111, 987-989.   | 1.2 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1009 | Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation.. Blood, 2004, 104, 5157-5157.                                | 0.6 | 0         |
| 1010 | Comparisson of Molecular Mechanisms Altered by Treatment with Different Drugs (Doxorubicin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Oligonucleotide Microarrays.. Blood, 2004, 104, 2457-2457.                              | 0.6 | 0         |
| 1011 | Comparison between Progenitor Cells from Mobilized Peripheral Blood (PB) in Healthy Donors and Non-Hodgkinâ€™s Lymphoma (NHL) Patients.. Blood, 2004, 104, 5002-5002.   | 0.6 | 0         |
| 1012 | NF-Î²B Blockade Induces Apoptosis and Decreases Costimulatory Molecules and IL-12 Secretion of Dendritic Cells, Altering DC Maturation: Role in Induction of Tolerance after Transplantation.. Blood, 2005, 106, 2465-2465. | 0.6 | 0         |
| 1013 | Endothelial Progenitor Cells (EPC) with Colony Forming Capacity Are Derived from the Monocytic-Macrophage Lineage.. Blood, 2005, 106, 4228-4228.  | 0.6 | 0         |
| 1014 | Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokineâ€™s Production Pattern.. Blood, 2005, 106, 615-615.   | 0.6 | 0         |
| 1015 | Influence of GST Gene Polimorphisms in the Develovement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 3084-3084.        | 0.6 | 0         |
| 1016 | Prognostic Factors and Classification in Multiple Myeloma. Translational Medicine Series, 2007, , 115-140.  | 0.0 | 0         |
| 1017 | Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 4743-4743.  | 0.6 | 0         |
| 1018 | The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3014-3014.                                  | 0.6 | 0         |
| 1019 | The Novel Combination of Sirolimus and Bortezomib Prevents Graft-Versus-Host Disease but Mantains the Graft-Versus-Leukemia Effect After Allogeneic Transplantation.. Blood, 2010, 116, 3738-3738.                          | 0.6 | 0         |
| 1020 | Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone. Blood, 2010, 116, 1906-1906.          | 0.6 | 0         |
| 1021 | Effect of Demethylating Agents (5-Azacytidine/5-AzaC) On the Immune Response. Blood, 2010, 116, 2771-2771.  | 0.6 | 0         |
| 1022 | Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis. Blood, 2010, 116, 4051-4051.  | 0.6 | 0         |
| 1023 | Effect of 5-Azacytidine (5-AzaC) In the Expression of PRAME In Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3615-3615.   | 0.6 | 0         |
| 1024 | Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting. Blood, 2010, 116, SCI-5-SCI-5.   | 0.6 | 0         |
| 1025 | Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,. Blood, 2011, 118, 3810-3810.   | 0.6 | 0         |
| 1026 | Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients,. Blood, 2011, 118, 3944-3944.   | 0.6 | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1027 | Phase I/II Clinical Trial for the Evaluation of Bortezomib within the Reduced Intensity Conditioning Regimen (RIC) and Post-Allogeneic Transplantation As Gvhd Prophylaxis Among High-Risk Myeloma Patients. EudraCT: 2005â€“004858-27. Blood, 2011, 118, 3025-3025. | 0.6 | 0         |
| 1028 | High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 630-630.        | 0.6 | 0         |
| 1029 | Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.  | 0.6 | 0         |
| 1030 | 6q Deletion Helps in the Discrimination Between Symptomatic Waldenströ`m's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies. Blood, 2012, 120, 4566-4566.   | 0.6 | 0         |
| 1031 | Transcriptome Analysis Reveals Molecular Profiles Associated with Evolving Steps of Monoclonal Gammopathies.. Blood, 2012, 120, 2914-2914.   | 0.6 | 0         |
| 1032 | Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC). Blood, 2012, 120, 3949-3949.                    | 0.6 | 0         |
| 1033 | Multiparameter Flow Cytometry (MFC) for Identification of the Waldenströ`m's Clone in IgM MGUS and Waldenstrom's Macroglobulinemia (WM): New Criteria for Differential Diagnosis and Risk Stratification. Blood, 2012, 120, 936-936.                                 | 0.6 | 0         |
| 1034 | Phenotypic, Functional and Circadian Characterization of Peripheral Blood (PB) Multiple Myeloma (MM) Circulating Tumor Cells (CTCs). Blood, 2012, 120, 726-726.  | 0.6 | 0         |
| 1035 | Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS. Blood, 2013, 122, 400-400.   | 0.6 | 0         |
| 1036 | Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity. Blood, 2013, 122, 531-531.   | 0.6 | 0         |
| 1037 | Minimal Residual Disease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia. Blood, 2013, 122, 2576-2576.   | 0.6 | 0         |
| 1038 | Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL). Blood, 2013, 122, 1841-1841.   | 0.6 | 0         |
| 1039 | Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. Blood, 2013, 122, 4611-4611.   | 0.6 | 0         |
| 1040 | Defects In DNA Double-Strand Break Repair and Increased Alternative Non-Homologous End Joining Pathways In Multiple Myeloma: Implications For Genome Stability. Blood, 2013, 122, 4882-4882.   | 0.6 | 0         |
| 1041 | Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.   | 0.6 | 0         |
| 1042 | Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). Blood, 2013, 122, 402-402.  | 0.6 | 0         |
| 1043 | Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients. Blood, 2013, 122, 1848-1848.   | 0.6 | 0         |
| 1044 | Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL). Blood, 2014, 124, 2135-2135.   | 0.6 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1045 | Intraclonal Heterogeneity Associates with Clonal Stability in Multiple Myeloma. <i>Blood</i> , 2014, 124, 3412-3412.  | 0.6 | 0         |
| 1046 | Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. <i>Blood</i> , 2014, 124, 2108-2108.   | 0.6 | 0         |
| 1047 | Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial. <i>Blood</i> , 2015, 126, 4504-4504.   | 0.6 | 0         |
| 1048 | Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2963-2963.  | 0.6 | 0         |
| 1049 | Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment. <i>Blood</i> , 2015, 126, 4230-4230.             | 0.6 | 0         |
| 1050 | Simplified in-House Deep Sequencing Method of Immunoglobulin Genes for Minimal Residual Disease Quantification and Risk Stratification in Multiple Myeloma. <i>Blood</i> , 2015, 126, 2972-2972.  | 0.6 | 0         |
| 1051 | Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 2955-2955.  | 0.6 | 0         |
| 1052 | Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 2078-2078.  | 0.6 | 0         |
| 1053 | Whole-Genome Analysis of the Chromatin Structure in Multiple Myeloma. <i>Blood</i> , 2016, 128, 118-118.  | 0.6 | 0         |
| 1054 | Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 474-474.  | 0.6 | 0         |
| 1055 | Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. <i>Blood</i> , 2018, 132, 188-188.   | 0.6 | 0         |
| 1056 | Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2018, 132, 4488-4488.  | 0.6 | 0         |
| 1057 | Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM). <i>Blood</i> , 2018, 132, 3550-3550. | 0.6 | 0         |
| 1058 | Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. <i>Blood</i> , 2018, 132, 4503-4503.  | 0.6 | 0         |
| 1059 | Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 3170-3170.   | 0.6 | 0         |
| 1060 | Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials. <i>Blood</i> , 2018, 132, 1964-1964.   | 0.6 | 0         |
| 1061 | PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (Dâ€¦RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK. <i>HemaSphere</i> , 2019, 3, 247-248.  | 1.2 | 0         |
| 1062 | Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4356-4356.   | 0.6 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1063 | Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3084-3084.  | 0.6 | 0         |
| 1064 | A Computational Based Approach for Identification and Validation of Gene Mutations As Surrogate Markers of Gene Essentiality in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1414-1414.                  | 0.6 | 0         |
| 1065 | A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 1596-1596.    | 0.6 | 0         |
| 1066 | Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. <i>Blood</i> , 2021, 138, 5031-5031.   | 0.6 | 0         |
| 1067 | Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 520-520. | 0.6 | 0         |